{"GO:0097289": "{\"taxon\": {\"id\": null, \"label\": null}, \"xrefs\": null, \"categories\": [\"cellular process\", \"biological process\"], \"deprecated\": null, \"replaced_by\": null, \"description\": null, \"synonyms\": [{\"val\": \"alpha-ribazole metabolism\", \"xrefs\": null, \"pred\": \"synonym\"}], \"types\": null, \"consider\": null, \"id\": \"GO:0097289\", \"label\": \"alpha-ribazole metabolic process\"}", "UBERON:0004476": "{\"xrefs\": null, \"taxon\": {\"id\": null, \"label\": null}, \"categories\": [\"anatomical entity\"], \"types\": null, \"description\": null, \"replaced_by\": null, \"consider\": null, \"synonyms\": [{\"val\": \"set of muscles of shoulder\", \"xrefs\": null, \"pred\": \"synonym\"}, {\"val\": \"muscle group of shoulder\", \"xrefs\": null, \"pred\": \"synonym\"}], \"deprecated\": null, \"id\": \"UBERON:0004476\", \"label\": \"musculature of shoulder\"}", "HP:0011515": "{\"xrefs\": null, \"taxon\": {\"id\": null, \"label\": null}, \"categories\": [\"Phenotype\"], \"types\": null, \"description\": null, \"replaced_by\": null, \"consider\": null, \"synonyms\": null, \"deprecated\": null, \"id\": \"HP:0011515\", \"label\": \"Abnormal stereopsis\"}", "DOID:3965": "{\"xrefs\": null, \"taxon\": {\"id\": null, \"label\": null}, \"categories\": [\"disease\", \"quality\"], \"types\": null, \"description\": null, \"replaced_by\": null, \"consider\": null, \"synonyms\": null, \"deprecated\": null, \"id\": \"DOID:3965\", \"label\": null}", "CHEMBL1201217": "{\"_id\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"aeolus\": {\"_license\": \"https://goo.gl/pLRNT8\", \"drug_id\": \"992308\", \"drug_name\": \"dyclonine\", \"drug_rxcui\": \"23744\", \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"indications\": [{\"count\": 1, \"id\": \"35708044\", \"meddra_code\": \"10009900\", \"name\": \"Colitis ulcerative\"}, {\"count\": 1, \"id\": \"36516830\", \"meddra_code\": \"10061371\", \"name\": \"Spondylitis\"}], \"no_of_outcomes\": 99, \"outcomes\": [{\"case_count\": 5, \"id\": \"35708044\", \"meddra_code\": \"10009900\", \"name\": \"Colitis ulcerative\", \"prr\": 138.60563, \"prr_95_ci\": [58.82637, 326.58011], \"ror\": 144.97626, \"ror_95_ci\": [59.137190000000004, 355.41283]}, {\"case_count\": 3, \"id\": \"35809054\", \"meddra_code\": \"10037660\", \"name\": \"Pyrexia\", \"prr\": 3.76462, \"prr_95_ci\": [1.23264, 11.49757], \"ror\": 3.8400199999999995, \"ror_95_ci\": [1.2196200000000001, 12.09044]}, {\"case_count\": 3, \"id\": \"37320197\", \"meddra_code\": \"10037087\", \"name\": \"Pruritus\", \"prr\": 5.95399, \"prr_95_ci\": [1.9495, 18.184179999999998], \"ror\": 6.0891, \"ror_95_ci\": [1.9339400000000002, 19.171789999999998]}, {\"case_count\": 2, \"id\": \"35809327\", \"meddra_code\": \"10013709\", \"name\": \"Drug ineffective\", \"prr\": 1.71187, \"prr_95_ci\": [0.43343000000000004, 6.7612], \"ror\": 1.7247, \"ror_95_ci\": [0.426, 6.98255]}, {\"case_count\": 2, \"id\": \"36110742\", \"meddra_code\": \"10051564\", \"name\": \"Haematoma infection\", \"prr\": 831.7196799999999, \"prr_95_ci\": [210.35636, 3288.50355], \"ror\": 846.6876, \"ror_95_ci\": [208.9111, 3431.507]}, {\"case_count\": 2, \"id\": \"36110597\", \"meddra_code\": \"10035664\", \"name\": \"Pneumonia\", \"prr\": 2.96515, \"prr_95_ci\": [0.75075, 11.711160000000001], \"ror\": 3.0005599999999997, \"ror_95_ci\": [0.7411399999999999, 12.14798]}, {\"case_count\": 2, \"id\": \"36718132\", \"meddra_code\": \"10019211\", \"name\": \"Headache\", \"prr\": 2.13089, \"prr_95_ci\": [0.53952, 8.416160000000001], \"ror\": 2.1512700000000002, \"ror_95_ci\": [0.53137, 8.70955]}, {\"case_count\": 2, \"id\": \"36718526\", \"meddra_code\": \"10010904\", \"name\": \"Convulsion\", \"prr\": 5.57584, \"prr_95_ci\": [1.41174, 22.02238], \"ror\": 5.65828, \"ror_95_ci\": [1.3976, 22.90803]}, {\"case_count\": 2, \"id\": \"37219907\", \"meddra_code\": \"10011224\", \"name\": \"Cough\", \"prr\": 4.45824, \"prr_95_ci\": [1.12878, 17.6083], \"ror\": 4.52055, \"ror_95_ci\": [1.11658, 18.30181]}, {\"case_count\": 1, \"id\": \"35707529\", \"meddra_code\": \"10034283\", \"name\": \"Penetrating abdominal trauma\", \"prr\": 25565.47872, \"prr_95_ci\": [3468.1111899999996, 188458.11624], \"ror\": 25793.73299, \"ror_95_ci\": [3440.01866, 193404.95721]}, {\"case_count\": 1, \"id\": \"35708248\", \"meddra_code\": \"10050396\", \"name\": \"Subileus\", \"prr\": 131.55478, \"prr_95_ci\": [18.68786, 926.09119], \"ror\": 132.72045, \"ror_95_ci\": [18.52786, 950.71529]}, {\"case_count\": 1, \"id\": \"35708634\", \"meddra_code\": \"10031118\", \"name\": \"Oropharyngeal swelling\", \"prr\": 237.03092999999998, \"prr_95_ci\": [33.664640000000006, 1668.92229], \"ror\": 239.13835, \"ror_95_ci\": [33.37746, 1713.3461]}, {\"case_count\": 1, \"id\": \"35741459\", \"meddra_code\": \"10034844\", \"name\": \"Pharyngolaryngeal pain\", \"prr\": 27.95205, \"prr_95_ci\": [3.97145, 196.7335], \"ror\": 28.192690000000002, \"ror_95_ci\": [3.93646, 201.91448]}, {\"case_count\": 1, \"id\": \"35809120\", \"meddra_code\": \"10061818\", \"name\": \"Disease progression\", \"prr\": 5.28733, \"prr_95_ci\": [0.75126, 37.21197], \"ror\": 5.32561, \"ror_95_ci\": [0.74363, 38.14011]}, {\"case_count\": 1, \"id\": \"35809304\", \"meddra_code\": \"10069327\", \"name\": \"Product quality issue\", \"prr\": 5.634119999999999, \"prr_95_ci\": [0.80053, 39.6527], \"ror\": 5.67549, \"ror_95_ci\": [0.7924800000000001, 40.64591]}, {\"case_count\": 1, \"id\": \"36045339\", \"meddra_code\": \"10002473\", \"name\": \"Angioneurotic oedema\", \"prr\": 60.65014, \"prr_95_ci\": [8.6167, 426.89639000000005], \"ror\": 61.18273000000001, \"ror_95_ci\": [8.54225, 438.2133]}, {\"case_count\": 1, \"id\": \"36211195\", \"meddra_code\": \"10049193\", \"name\": \"Drug exposure during pregnancy\", \"prr\": 6.99384, \"prr_95_ci\": [0.9937299999999999, 49.22249], \"ror\": 7.04736, \"ror_95_ci\": [0.9840399999999999, 50.47084]}, {\"case_count\": 1, \"id\": \"36211280\", \"meddra_code\": \"10000369\", \"name\": \"Accident\", \"prr\": 63.50545, \"prr_95_ci\": [9.02232, 446.99629000000004], \"ror\": 64.06353, \"ror_95_ci\": [8.944410000000001, 458.84902999999997]}, {\"case_count\": 1, \"id\": \"36312568\", \"meddra_code\": \"10059570\", \"name\": \"Blood alkaline phosphatase increased\", \"prr\": 8.346160000000001, \"prr_95_ci\": [1.18587, 58.74024], \"ror\": 8.41175, \"ror_95_ci\": [1.17455, 60.24233]}, {\"case_count\": 1, \"id\": \"36313436\", \"meddra_code\": \"10029366\", \"name\": \"Neutrophil count decreased\", \"prr\": 12.00794, \"prr_95_ci\": [1.70615, 84.51241], \"ror\": 12.10623, \"ror_95_ci\": [1.6904, 86.7016]}, {\"case_count\": 1, \"id\": \"36313550\", \"meddra_code\": \"10005364\", \"name\": \"Blood bilirubin increased\", \"prr\": 10.400730000000001, \"prr_95_ci\": [1.47779, 73.20054], \"ror\": 10.48466, \"ror_95_ci\": [1.46399, 75.08815]}, {\"case_count\": 1, \"id\": \"36617371\", \"meddra_code\": \"10017709\", \"name\": \"Ganglioneuroma\", \"prr\": 4588.6756700000005, \"prr_95_ci\": [646.5452799999999, 32566.85172], \"ror\": 4629.63706, \"ror_95_ci\": [641.0976900000001, 33432.56366]}, {\"case_count\": 1, \"id\": \"36919230\", \"meddra_code\": \"10010144\", \"name\": \"Completed suicide\", \"prr\": 5.23724, \"prr_95_ci\": [0.7441399999999999, 36.85949], \"ror\": 5.27508, \"ror_95_ci\": [0.73657, 37.778240000000004]}, {\"case_count\": 1, \"id\": \"37320167\", \"meddra_code\": \"10064579\", \"name\": \"Exfoliative rash\", \"prr\": 145.14059, \"prr_95_ci\": [20.61726, 1021.75514], \"ror\": 146.42756, \"ror_95_ci\": [20.44087, 1048.9292599999999]}, {\"case_count\": 1, \"id\": \"37320213\", \"meddra_code\": \"10037858\", \"name\": \"Rash generalised\", \"prr\": 12.41933, \"prr_95_ci\": [1.7646, 87.40782], \"ror\": 12.52128, \"ror_95_ci\": [1.74836, 89.6742]}, {\"case_count\": 1, \"id\": \"37521041\", \"meddra_code\": \"10061778\", \"name\": \"Colectomy\", \"prr\": 161.75808, \"prr_95_ci\": [22.977079999999997, 1138.77295], \"ror\": 163.19342, \"ror_95_ci\": [22.78065, 1169.06622]}, {\"case_count\": 1, \"id\": \"37522220\", \"meddra_code\": \"10053762\", \"name\": \"Off label use\", \"prr\": 3.31839, \"prr_95_ci\": [0.4715, 23.354570000000002], \"ror\": 3.33909, \"ror_95_ci\": [0.46625, 23.91327]}, {\"case_count\": 1, \"id\": \"37586547\", \"meddra_code\": \"10052521\", \"name\": \"Nasal sinus drainage\", \"prr\": 1731.8550100000002, \"prr_95_ci\": [245.29643, 12227.33555], \"ror\": 1747.30907, \"ror_95_ci\": [243.21769, 12552.90688]}, {\"case_count\": 1, \"id\": \"35204948\", \"meddra_code\": \"10043071\", \"name\": \"Tachycardia\", \"prr\": 4.5163, \"prr_95_ci\": [0.64171, 31.78547], \"ror\": 4.54769, \"ror_95_ci\": [0.6350100000000001, 32.568940000000005]}, {\"case_count\": 1, \"id\": \"35205025\", \"meddra_code\": \"10013573\", \"name\": \"Dizziness\", \"prr\": 1.09514, \"prr_95_ci\": [0.15561, 7.707489999999999], \"ror\": 1.09599, \"ror_95_ci\": [0.15304, 7.84903]}, {\"case_count\": 1, \"id\": \"35205034\", \"meddra_code\": \"10033557\", \"name\": \"Palpitations\", \"prr\": 4.29531, \"prr_95_ci\": [0.61031, 30.23015], \"ror\": 4.324730000000001, \"ror_95_ci\": [0.60387, 30.97215]}, {\"case_count\": 1, \"id\": \"35205184\", \"meddra_code\": \"10008469\", \"name\": \"Chest discomfort\", \"prr\": 4.9051599999999995, \"prr_95_ci\": [0.69696, 34.5223], \"ror\": 4.94003, \"ror_95_ci\": [0.68979, 35.37874]}, {\"case_count\": 1, \"id\": \"35205185\", \"meddra_code\": \"10008479\", \"name\": \"Chest pain\", \"prr\": 1.8427799999999999, \"prr_95_ci\": [0.26184, 12.96931], \"ror\": 1.8503, \"ror_95_ci\": [0.25836, 13.25114]}, {\"case_count\": 1, \"id\": \"35205388\", \"meddra_code\": \"10034474\", \"name\": \"Pericardial effusion\", \"prr\": 14.91651, \"prr_95_ci\": [2.1194, 104.98361000000001], \"ror\": 15.040770000000002, \"ror_95_ci\": [2.10015, 107.71856000000001]}, {\"case_count\": 1, \"id\": \"35506609\", \"meddra_code\": \"10012601\", \"name\": \"Diabetes mellitus\", \"prr\": 3.7522699999999998, \"prr_95_ci\": [0.53315, 26.40825], \"ror\": 3.77685, \"ror_95_ci\": [0.52737, 27.048370000000002]}, {\"case_count\": 1, \"id\": \"35606824\", \"meddra_code\": \"10007739\", \"name\": \"Cataract\", \"prr\": 8.52792, \"prr_95_ci\": [1.2117, 60.01947], \"ror\": 8.595130000000001, \"ror_95_ci\": [1.20015, 61.55566999999999]}, {\"case_count\": 1, \"id\": \"35607483\", \"meddra_code\": \"10047513\", \"name\": \"Vision blurred\", \"prr\": 3.84611, \"prr_95_ci\": [0.54648, 27.0687], \"ror\": 3.87152, \"ror_95_ci\": [0.54059, 27.72643]}, {\"case_count\": 1, \"id\": \"35707872\", \"meddra_code\": \"10048946\", \"name\": \"Anal abscess\", \"prr\": 147.08906000000002, \"prr_95_ci\": [20.89397, 1035.47555], \"ror\": 148.39342, \"ror_95_ci\": [20.71523, 1063.0154]}, {\"case_count\": 1, \"id\": \"35707960\", \"meddra_code\": \"10017964\", \"name\": \"Gastrointestinal infection\", \"prr\": 74.27712, \"prr_95_ci\": [10.55246, 522.8253], \"ror\": 74.93138, \"ror_95_ci\": [10.46156, 536.6995099999999]}, {\"case_count\": 1, \"id\": \"35708006\", \"meddra_code\": \"10058838\", \"name\": \"Enterocolitis infectious\", \"prr\": 241.61794, \"prr_95_ci\": [34.31582, 1701.23347], \"ror\": 243.76631, \"ror_95_ci\": [34.02312, 1746.5184600000002]}, {\"case_count\": 1, \"id\": \"35708093\", \"meddra_code\": \"10012735\", \"name\": \"Diarrhoea\", \"prr\": 0.9866299999999999, \"prr_95_ci\": [0.14019, 6.94382], \"ror\": 0.98651, \"ror_95_ci\": [0.13775, 7.065]}, {\"case_count\": 1, \"id\": \"35708139\", \"meddra_code\": \"10013946\", \"name\": \"Dyspepsia\", \"prr\": 4.95643, \"prr_95_ci\": [0.70424, 34.88309], \"ror\": 4.99175, \"ror_95_ci\": [0.69701, 35.749140000000004]}, {\"case_count\": 1, \"id\": \"35708202\", \"meddra_code\": \"10028813\", \"name\": \"Nausea\", \"prr\": 0.6995, \"prr_95_ci\": [0.09938999999999999, 4.923030000000001], \"ror\": 0.69682, \"ror_95_ci\": [0.0973, 4.99034]}, {\"case_count\": 1, \"id\": \"35708208\", \"meddra_code\": \"10047700\", \"name\": \"Vomiting\", \"prr\": 1.05345, \"prr_95_ci\": [0.14968, 7.41408], \"ror\": 1.05393, \"ror_95_ci\": [0.14715999999999999, 7.5478]}, {\"case_count\": 1, \"id\": \"35708609\", \"meddra_code\": \"10043521\", \"name\": \"Throat irritation\", \"prr\": 15.84637, \"prr_95_ci\": [2.2515099999999997, 111.52823000000001], \"ror\": 15.978929999999998, \"ror_95_ci\": [2.2311400000000003, 114.43766000000001]}, {\"case_count\": 1, \"id\": \"35809059\", \"meddra_code\": \"10011906\", \"name\": \"Death\", \"prr\": 1.3851, \"prr_95_ci\": [0.19680999999999998, 9.74821], \"ror\": 1.3885399999999999, \"ror_95_ci\": [0.19389, 9.94416]}, {\"case_count\": 1, \"id\": \"35809065\", \"meddra_code\": \"10022747\", \"name\": \"Intra-uterine death\", \"prr\": 127.16131000000001, \"prr_95_ci\": [18.06389, 895.15578], \"ror\": 128.28775, \"ror_95_ci\": [17.90919, 918.95526]}, {\"case_count\": 1, \"id\": \"35809072\", \"meddra_code\": \"10003549\", \"name\": \"Asthenia\", \"prr\": 1.25401, \"prr_95_ci\": [0.17818, 8.825619999999999], \"ror\": 1.2562799999999998, \"ror_95_ci\": [0.17542, 8.99697]}, {\"case_count\": 1, \"id\": \"35809076\", \"meddra_code\": \"10016256\", \"name\": \"Fatigue\", \"prr\": 0.9117, \"prr_95_ci\": [0.12954000000000002, 6.41645], \"ror\": 0.91091, \"ror_95_ci\": [0.12719, 6.523569999999999]}, {\"case_count\": 1, \"id\": \"35809079\", \"meddra_code\": \"10025482\", \"name\": \"Malaise\", \"prr\": 1.55075, \"prr_95_ci\": [0.22034, 10.914019999999999], \"ror\": 1.55567, \"ror_95_ci\": [0.21721999999999997, 11.14105]}, {\"case_count\": 1, \"id\": \"35809185\", \"meddra_code\": \"10036141\", \"name\": \"Polyserositis\", \"prr\": 1111.54255, \"prr_95_ci\": [157.61556000000002, 7838.863609999999], \"ror\": 1121.45811, \"ror_95_ci\": [156.27784, 8047.64295]}, {\"case_count\": 1, \"id\": \"35909513\", \"meddra_code\": \"10000804\", \"name\": \"Acute hepatic failure\", \"prr\": 41.44473, \"prr_95_ci\": [5.88835, 291.70556], \"ror\": 41.80585, \"ror_95_ci\": [5.83708, 299.41844]}, {\"case_count\": 1, \"id\": \"35909682\", \"meddra_code\": \"10027457\", \"name\": \"Metastases to liver\", \"prr\": 25.19949, \"prr_95_ci\": [3.5803800000000003, 177.35936999999998], \"ror\": 25.41555, \"ror_95_ci\": [3.54871, 182.02383999999998]}, {\"case_count\": 1, \"id\": \"36009700\", \"meddra_code\": \"10003553\", \"name\": \"Asthma\", \"prr\": 5.60056, \"prr_95_ci\": [0.79576, 39.4165], \"ror\": 5.64163, \"ror_95_ci\": [0.78776, 40.403420000000004]}, {\"case_count\": 1, \"id\": \"36009708\", \"meddra_code\": \"10015226\", \"name\": \"Erythema nodosum\", \"prr\": 177.06961, \"prr_95_ci\": [25.151310000000002, 1246.60076], \"ror\": 178.64166, \"ror_95_ci\": [24.936420000000002, 1279.7681699999998]}, {\"case_count\": 1, \"id\": \"36009735\", \"meddra_code\": \"10012442\", \"name\": \"Dermatitis contact\", \"prr\": 56.650319999999994, \"prr_95_ci\": [8.0485, 398.74002], \"ror\": 57.14719, \"ror_95_ci\": [7.97887, 409.30632]}, {\"case_count\": 1, \"id\": \"36009833\", \"meddra_code\": \"10039073\", \"name\": \"Rheumatoid arthritis\", \"prr\": 7.491560000000001, \"prr_95_ci\": [1.06445, 52.725480000000005], \"ror\": 7.549519999999999, \"ror_95_ci\": [1.05416, 54.06721999999999]}, {\"case_count\": 1, \"id\": \"36110229\", \"meddra_code\": \"10058080\", \"name\": \"Staphylococcal infection\", \"prr\": 8.977689999999999, \"prr_95_ci\": [1.2756, 63.18505], \"ror\": 9.048919999999999, \"ror_95_ci\": [1.26352, 64.80564]}, {\"case_count\": 1, \"id\": \"36110472\", \"meddra_code\": \"10006171\", \"name\": \"Breast abscess\", \"prr\": 484.10735, \"prr_95_ci\": [68.72487, 3410.11834], \"ror\": 488.42080999999996, \"ror_95_ci\": [68.14019, 3500.94246]}, {\"case_count\": 1, \"id\": \"36110534\", \"meddra_code\": \"10000269\", \"name\": \"Abscess\", \"prr\": 25.546020000000002, \"prr_95_ci\": [3.62961, 179.79842], \"ror\": 25.765179999999997, \"ror_95_ci\": [3.5975300000000003, 184.52792]}, {\"case_count\": 1, \"id\": \"36110540\", \"meddra_code\": \"10064687\", \"name\": \"Device related infection\", \"prr\": 26.901590000000002, \"prr_95_ci\": [3.8222099999999997, 189.33973], \"ror\": 27.132859999999997, \"ror_95_ci\": [3.7884800000000003, 194.3236]}, {\"case_count\": 1, \"id\": \"36110552\", \"meddra_code\": \"10021789\", \"name\": \"Infection\", \"prr\": 4.57456, \"prr_95_ci\": [0.64999, 32.19552], \"ror\": 4.60648, \"ror_95_ci\": [0.64322, 32.98992]}, {\"case_count\": 1, \"id\": \"36110584\", \"meddra_code\": \"10006451\", \"name\": \"Bronchitis\", \"prr\": 5.013730000000001, \"prr_95_ci\": [0.71238, 35.286390000000004], \"ror\": 5.04957, \"ror_95_ci\": [0.70508, 36.16319]}, {\"case_count\": 1, \"id\": \"36110715\", \"meddra_code\": \"10046306\", \"name\": \"Upper respiratory tract infection\", \"prr\": 9.54988, \"prr_95_ci\": [1.3569, 67.21215], \"ror\": 9.62622, \"ror_95_ci\": [1.34412, 68.94011]}, {\"case_count\": 1, \"id\": \"36110716\", \"meddra_code\": \"10011781\", \"name\": \"Cystitis\", \"prr\": 14.93061, \"prr_95_ci\": [2.1214, 105.08288], \"ror\": 15.055, \"ror_95_ci\": [2.10213, 107.82047]}, {\"case_count\": 1, \"id\": \"36110766\", \"meddra_code\": \"10013453\", \"name\": \"Disseminated tuberculosis\", \"prr\": 151.48845, \"prr_95_ci\": [21.518720000000002, 1066.45492], \"ror\": 152.83209, \"ror_95_ci\": [21.33468, 1094.82054]}, {\"case_count\": 1, \"id\": \"36110874\", \"meddra_code\": \"10011831\", \"name\": \"Cytomegalovirus infection\", \"prr\": 23.07056, \"prr_95_ci\": [3.27791, 162.37491], \"ror\": 23.26762, \"ror_95_ci\": [3.2488099999999998, 166.6399]}, {\"case_count\": 1, \"id\": \"36111047\", \"meddra_code\": \"10047461\", \"name\": \"Viral infection\", \"prr\": 16.844720000000002, \"prr_95_ci\": [2.39336, 118.55495], \"ror\": 16.9862, \"ror_95_ci\": [2.3717799999999998, 121.65171000000001]}, {\"case_count\": 1, \"id\": \"36211102\", \"meddra_code\": \"10020100\", \"name\": \"Hip fracture\", \"prr\": 16.06448, \"prr_95_ci\": [2.2825, 113.06336999999999], \"ror\": 16.19899, \"ror_95_ci\": [2.26186, 116.01373000000001]}, {\"case_count\": 1, \"id\": \"36211165\", \"meddra_code\": \"10013746\", \"name\": \"Drug toxicity\", \"prr\": 10.09866, \"prr_95_ci\": [1.43487, 71.07455999999999], \"ror\": 10.1799, \"ror_95_ci\": [1.42143, 72.90549]}, {\"case_count\": 1, \"id\": \"36211383\", \"meddra_code\": \"10005191\", \"name\": \"Blister\", \"prr\": 10.93788, \"prr_95_ci\": [1.55411, 76.98114], \"ror\": 11.02661, \"ror_95_ci\": [1.53966, 78.96954000000001]}, {\"case_count\": 1, \"id\": \"36211385\", \"meddra_code\": \"10050584\", \"name\": \"Contusion\", \"prr\": 5.12007, \"prr_95_ci\": [0.72749, 36.03481], \"ror\": 5.15686, \"ror_95_ci\": [0.72007, 36.93157]}, {\"case_count\": 1, \"id\": \"36211392\", \"meddra_code\": \"10058818\", \"name\": \"Skin laceration\", \"prr\": 61.816359999999996, \"prr_95_ci\": [8.78237, 435.10592], \"ror\": 62.359359999999995, \"ror_95_ci\": [8.70651, 446.64169000000004]}, {\"case_count\": 1, \"id\": \"36211496\", \"meddra_code\": \"10033295\", \"name\": \"Overdose\", \"prr\": 4.19666, \"prr_95_ci\": [0.59629, 29.53588], \"ror\": 4.22521, \"ror_95_ci\": [0.5899800000000001, 30.25938]}, {\"case_count\": 1, \"id\": \"36313476\", \"meddra_code\": \"10047942\", \"name\": \"White blood cell count decreased\", \"prr\": 4.618040000000001, \"prr_95_ci\": [0.6561600000000001, 32.501540000000006], \"ror\": 4.65035, \"ror_95_ci\": [0.6493399999999999, 33.3041]}, {\"case_count\": 1, \"id\": \"36314160\", \"meddra_code\": \"10005557\", \"name\": \"Blood glucose increased\", \"prr\": 2.41252, \"prr_95_ci\": [0.34279, 16.97912], \"ror\": 2.42513, \"ror_95_ci\": [0.33863000000000004, 17.36785]}, {\"case_count\": 1, \"id\": \"36314507\", \"meddra_code\": \"10061449\", \"name\": \"Culture positive\", \"prr\": 249.82552, \"prr_95_ci\": [35.48097, 1759.04962], \"ror\": 252.04717999999997, \"ror_95_ci\": [35.17838, 1805.87555]}, {\"case_count\": 1, \"id\": \"36315381\", \"meddra_code\": \"10047899\", \"name\": \"Weight increased\", \"prr\": 2.52948, \"prr_95_ci\": [0.35941, 17.8023], \"ror\": 2.54314, \"ror_95_ci\": [0.35511, 18.212970000000002]}, {\"case_count\": 1, \"id\": \"36516779\", \"meddra_code\": \"10003246\", \"name\": \"Arthritis\", \"prr\": 6.1702699999999995, \"prr_95_ci\": [0.87671, 43.42615], \"ror\": 6.21643, \"ror_95_ci\": [0.8680200000000001, 44.51997]}, {\"case_count\": 1, \"id\": \"36516781\", \"meddra_code\": \"10003285\", \"name\": \"Arthropathy\", \"prr\": 10.46214, \"prr_95_ci\": [1.48652, 73.63277], \"ror\": 10.546619999999999, \"ror_95_ci\": [1.47264, 75.5319]}, {\"case_count\": 1, \"id\": \"36516812\", \"meddra_code\": \"10003239\", \"name\": \"Arthralgia\", \"prr\": 1.6124, \"prr_95_ci\": [0.2291, 11.3479], \"ror\": 1.6178700000000001, \"ror_95_ci\": [0.22591, 11.5865]}, {\"case_count\": 1, \"id\": \"36617162\", \"meddra_code\": \"10006187\", \"name\": \"Breast cancer\", \"prr\": 8.6887, \"prr_95_ci\": [1.23454, 61.151109999999996], \"ror\": 8.75735, \"ror_95_ci\": [1.22281, 62.71748]}, {\"case_count\": 1, \"id\": \"36617821\", \"meddra_code\": \"10025031\", \"name\": \"Lung adenocarcinoma\", \"prr\": 144.67126000000002, \"prr_95_ci\": [20.55061, 1018.45029], \"ror\": 145.95404, \"ror_95_ci\": [20.37479, 1045.53631]}, {\"case_count\": 1, \"id\": \"36717962\", \"meddra_code\": \"10014581\", \"name\": \"Encephalitis\", \"prr\": 70.14307, \"prr_95_ci\": [9.96521, 493.72258], \"ror\": 70.76042, \"ror_95_ci\": [9.8793, 506.82097000000005]}, {\"case_count\": 1, \"id\": \"36718001\", \"meddra_code\": \"10008118\", \"name\": \"Cerebral infarction\", \"prr\": 14.280870000000002, \"prr_95_ci\": [2.02909, 100.50981], \"ror\": 14.39945, \"ror_95_ci\": [2.0106, 103.12548000000001]}, {\"case_count\": 1, \"id\": \"36718301\", \"meddra_code\": \"10010305\", \"name\": \"Confusional state\", \"prr\": 2.41645, \"prr_95_ci\": [0.34335, 17.00679], \"ror\": 2.4291, \"ror_95_ci\": [0.33918000000000004, 17.39626]}, {\"case_count\": 1, \"id\": \"36718372\", \"meddra_code\": \"10006784\", \"name\": \"Burning sensation\", \"prr\": 7.98707, \"prr_95_ci\": [1.13485, 56.21295], \"ror\": 8.04946, \"ror_95_ci\": [1.12396, 57.64767]}, {\"case_count\": 1, \"id\": \"36718406\", \"meddra_code\": \"10040026\", \"name\": \"Sensory disturbance\", \"prr\": 28.424129999999998, \"prr_95_ci\": [4.03852, 200.05631], \"ror\": 28.66899, \"ror_95_ci\": [4.00296, 205.32588]}, {\"case_count\": 1, \"id\": \"36718433\", \"meddra_code\": \"10041466\", \"name\": \"Speech disorder\", \"prr\": 8.79835, \"prr_95_ci\": [1.2501200000000001, 61.92276999999999], \"ror\": 8.86797, \"ror_95_ci\": [1.23825, 63.509719999999994]}, {\"case_count\": 1, \"id\": \"36718555\", \"meddra_code\": \"10022437\", \"name\": \"Insomnia\", \"prr\": 1.95507, \"prr_95_ci\": [0.27779, 13.75964], \"ror\": 1.9636, \"ror_95_ci\": [0.27418000000000003, 14.06254]}, {\"case_count\": 1, \"id\": \"36918985\", \"meddra_code\": \"10019070\", \"name\": \"Hallucination, auditory\", \"prr\": 27.598570000000002, \"prr_95_ci\": [3.9212300000000004, 194.24551], \"ror\": 27.836059999999996, \"ror_95_ci\": [3.8866699999999996, 199.36016]}, {\"case_count\": 1, \"id\": \"36918990\", \"meddra_code\": \"10019075\", \"name\": \"Hallucination, visual\", \"prr\": 21.56125, \"prr_95_ci\": [3.06347, 151.75165], \"ror\": 21.74483, \"ror_95_ci\": [3.0362, 155.73343]}, {\"case_count\": 1, \"id\": \"36919132\", \"meddra_code\": \"10066169\", \"name\": \"Substance abuse\", \"prr\": 69.49839, \"prr_95_ci\": [9.87363, 489.18422999999996], \"ror\": 70.10998000000001, \"ror_95_ci\": [9.7885, 502.16163]}, {\"case_count\": 1, \"id\": \"37019321\", \"meddra_code\": \"10062237\", \"name\": \"Renal impairment\", \"prr\": 5.09084, \"prr_95_ci\": [0.72334, 35.82911], \"ror\": 5.12737, \"ror_95_ci\": [0.71595, 36.72039]}, {\"case_count\": 1, \"id\": \"37019456\", \"meddra_code\": \"10029148\", \"name\": \"Nephrolithiasis\", \"prr\": 11.573830000000001, \"prr_95_ci\": [1.64447, 81.45702], \"ror\": 11.66823, \"ror_95_ci\": [1.62925, 83.56475]}, {\"case_count\": 1, \"id\": \"37320212\", \"meddra_code\": \"10037844\", \"name\": \"Rash\", \"prr\": 1.72629, \"prr_95_ci\": [0.24528000000000003, 12.14949], \"ror\": 1.73278, \"ror_95_ci\": [0.24195, 12.409460000000001]}, {\"case_count\": 1, \"id\": \"37420470\", \"meddra_code\": \"10061409\", \"name\": \"Victim of crime\", \"prr\": 774.7114799999999, \"prr_95_ci\": [109.92107, 5460.08028], \"ror\": 781.61961, \"ror_95_ci\": [108.98718000000001, 5605.5145600000005]}, {\"case_count\": 1, \"id\": \"37522270\", \"meddra_code\": \"10042609\", \"name\": \"Surgery\", \"prr\": 17.1252, \"prr_95_ci\": [2.43321, 120.52904], \"ror\": 17.26918, \"ror_95_ci\": [2.41129, 123.67843]}, {\"case_count\": 1, \"id\": \"37622518\", \"meddra_code\": \"10055798\", \"name\": \"Haemorrhage\", \"prr\": 5.8324300000000004, \"prr_95_ci\": [0.8287100000000001, 41.04842], \"ror\": 5.87558, \"ror_95_ci\": [0.82042, 42.07885]}], \"pt\": \"DYCLONINE\", \"rxcui\": \"23744\", \"unii\": \"078A24Q30O\"}, \"chebi\": {\"_license\": \"https://goo.gl/FJpLMf\", \"beilstein_registry_numbers\": \"224037\", \"cas_registry_numbers\": \"586-60-7\", \"charge\": 0, \"chebi_id\": \"CHEBI:4724\", \"chebi_name\": \"dyclonine\", \"definition\": \"<element>N</element>-Ethylpiperidine in which one of the hydrogens attached to the methyl group is substituted by a 4-butoxybenzoyl group.\", \"drugbank_database_links\": \"DB00645\", \"formulae\": \"C18H27NO2\", \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"inn\": [\"diclonina\", \"dyclonine\", \"dycloninum\"], \"iupac_names\": \"1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one\", \"kegg_drug_database_links\": \"D07881\", \"last_modified\": \"22 Feb 2017\", \"lincs_database_links\": \"LSM-5801\", \"mass\": 289.4125, \"monoisotopic_mass\": 289.204, \"pubchem_database_links\": [\"CID: 3180\", \"SID: 99319105\"], \"smiles\": \"CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1\", \"star\": 3, \"synonyms\": [\"1-(4-butoxyphenyl)-3-(1-piperidinyl)-1-propanone\", \"2-(1-piperidyl)ethyl p-butoxyphenyl ketone\", \"3-piperidino-4'-butoxypropiophenone\", \"4'-butoxy-3-piperidinopropiophenone\", \"4-butoxy-beta-piperidinopropiophenone\", \"4-n-butoxy-beta-(1-piperidyl)propiophenone\"], \"uniprot_database_links\": \"Q12529\", \"wikipedia_database_links\": \"Dyclonine\"}, \"chembl\": {\"_license\": \"https://goo.gl/FJpLMf\", \"atc_classifications\": [\"N01BX02\", \"R02AD04\"], \"availability_type\": 0, \"black_box_warning\": 0, \"chebi_par_id\": 4724, \"chirality\": 2, \"dosed_ingredient\": true, \"first_approval\": 1982, \"first_in_class\": 0, \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchi_key\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"indication_class\": \"Anesthetic (topical)\", \"inorganic_flag\": 0, \"max_phase\": 4, \"molecule_chembl_id\": \"CHEMBL1201217\", \"molecule_hierarchy\": {\"molecule_chembl_id\": \"CHEMBL1201217\", \"parent_chembl_id\": \"CHEMBL1201217\"}, \"molecule_properties\": {\"acd_logd\": 2.74, \"acd_logp\": 4.04, \"acd_most_bpka\": 8.68, \"alogp\": 4.05, \"aromatic_rings\": 1, \"full_molformula\": \"C18H27NO2\", \"full_mwt\": 289.41, \"hba\": 3, \"hba_lipinski\": 3, \"hbd\": 0, \"hbd_lipinski\": 0, \"heavy_atoms\": 21, \"molecular_species\": \"BASE\", \"mw_freebase\": 289.41, \"mw_monoisotopic\": 289.2042, \"num_alerts\": 2, \"num_lipinski_ro5_violations\": 0, \"num_ro5_violations\": 0, \"psa\": 29.54, \"qed_weighted\": 0.53, \"ro3_pass\": false, \"rtb\": 8}, \"molecule_synonyms\": [{\"molecule_synonym\": \"Dyclonine\", \"syn_type\": \"OTHER\", \"synonyms\": \"Dyclonine\"}, {\"molecule_synonym\": \"Dyclonine\", \"syn_type\": \"BAN\", \"synonyms\": \"DYCLONINE\"}, {\"molecule_synonym\": \"Dyclonine\", \"syn_type\": \"INN\", \"synonyms\": \"DYCLONINE\"}, {\"molecule_synonym\": \"Dyclonine\", \"syn_type\": \"ATC\", \"synonyms\": \"DYCLONINE\"}], \"molecule_type\": \"Small molecule\", \"natural_product\": 0, \"oral\": false, \"parenteral\": false, \"polymer_flag\": false, \"pref_name\": \"DYCLONINE\", \"prodrug\": 0, \"smiles\": \"CCCCOc1ccc(cc1)C(=O)CCN2CCCCC2\", \"structure_type\": \"MOL\", \"therapeutic_flag\": true, \"topical\": true, \"withdrawn_flag\": false}, \"drugbank\": {\"_license\": \"https://goo.gl/kvVASD\", \"accession_number\": \"APRD00940\", \"ahfs_codes\": \"52:16.00\", \"atc_codes\": [\"N01BX02\", \"R02AD04\"], \"categories\": [{\"category\": \"Anesthetics\", \"mesh-id\": \"D000777\"}, {\"category\": \"Anesthetics, Local\", \"mesh-id\": \"D000779\"}, {\"category\": \"Central Nervous System Agents\", \"mesh-id\": \"D002491\"}, {\"category\": \"Central Nervous System Depressants\", \"mesh-id\": \"D002492\"}, {\"category\": \"Chemical Actions and Uses\", \"mesh-id\": \"D020164\"}, {\"category\": \"Ketones\", \"mesh-id\": \"D007659\"}, {\"category\": \"Organic Chemicals\", \"mesh-id\": \"D009930\"}, {\"category\": \"Peripheral Nervous System Agents\", \"mesh-id\": \"D018373\"}, {\"category\": \"Pharmacologic Actions\", \"mesh-id\": \"D020228\"}, {\"category\": \"Physiological Effects of Drugs\", \"mesh-id\": \"D045505\"}, {\"category\": \"Respiratory System\", \"mesh-id\": \"D012137\"}, {\"category\": \"Sensory System Agents\", \"mesh-id\": \"D018689\"}, {\"category\": \"Therapeutic Uses\", \"mesh-id\": \"D045506\"}, {\"category\": \"Throat Preparations\"}], \"chebi\": \"4724\", \"chembl\": \"CHEMBL1201217\", \"chemspider\": \"3068\", \"dpd\": \"5669\", \"drug_interactions\": [{\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.\", \"drugbank-id\": \"DB00921\", \"name\": \"Buprenorphine\"}, {\"description\": \"Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00557\", \"name\": \"Hydroxyzine\"}, {\"description\": \"The therapeutic efficacy of Dyclonine can be increased when used in combination with Magnesium sulfate.\", \"drugbank-id\": \"DB00653\", \"name\": \"Magnesium sulfate\"}, {\"description\": \"Dyclonine may increase the sedative activities of Metyrosine.\", \"drugbank-id\": \"DB00765\", \"name\": \"Metyrosine\"}, {\"description\": \"Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB01017\", \"name\": \"Minocycline\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.\", \"drugbank-id\": \"DB00370\", \"name\": \"Mirtazapine\"}, {\"description\": \"Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00486\", \"name\": \"Nabilone\"}, {\"description\": \"Dyclonine may increase the sedative activities of Pramipexole.\", \"drugbank-id\": \"DB00413\", \"name\": \"Pramipexole\"}, {\"description\": \"Dyclonine may increase the sedative activities of Ropinirole.\", \"drugbank-id\": \"DB00268\", \"name\": \"Ropinirole\"}, {\"description\": \"Dyclonine may increase the sedative activities of Rotigotine.\", \"drugbank-id\": \"DB05271\", \"name\": \"Rotigotine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine.\", \"drugbank-id\": \"DB06201\", \"name\": \"Rufinamide\"}, {\"description\": \"The therapeutic efficacy of Dyclonine can be increased when used in combination with Pregabalin.\", \"drugbank-id\": \"DB00230\", \"name\": \"Pregabalin\"}, {\"description\": \"Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00470\", \"name\": \"Dronabinol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.\", \"drugbank-id\": \"DB00070\", \"name\": \"Hyaluronidase\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB00186\", \"name\": \"Lorazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.\", \"drugbank-id\": \"DB00193\", \"name\": \"Tramadol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine.\", \"drugbank-id\": \"DB00206\", \"name\": \"Reserpine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB00231\", \"name\": \"Temazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine.\", \"drugbank-id\": \"DB00237\", \"name\": \"Butabarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine.\", \"drugbank-id\": \"DB00246\", \"name\": \"Ziprasidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine.\", \"drugbank-id\": \"DB00295\", \"name\": \"Morphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.\", \"drugbank-id\": \"DB00312\", \"name\": \"Pentobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.\", \"drugbank-id\": \"DB00318\", \"name\": \"Codeine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine.\", \"drugbank-id\": \"DB00327\", \"name\": \"Hydromorphone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.\", \"drugbank-id\": \"DB00333\", \"name\": \"Methadone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine.\", \"drugbank-id\": \"DB00334\", \"name\": \"Olanzapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine.\", \"drugbank-id\": \"DB00363\", \"name\": \"Clozapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.\", \"drugbank-id\": \"DB00371\", \"name\": \"Meprobamate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.\", \"drugbank-id\": \"DB00402\", \"name\": \"Eszopiclone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.\", \"drugbank-id\": \"DB00404\", \"name\": \"Alprazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.\", \"drugbank-id\": \"DB00408\", \"name\": \"Loxapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.\", \"drugbank-id\": \"DB00418\", \"name\": \"Secobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00420\", \"name\": \"Promazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00433\", \"name\": \"Prochlorperazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine.\", \"drugbank-id\": \"DB00454\", \"name\": \"Pethidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.\", \"drugbank-id\": \"DB00474\", \"name\": \"Methohexital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine.\", \"drugbank-id\": \"DB00475\", \"name\": \"Chlordiazepoxide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00477\", \"name\": \"Chlorpromazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine.\", \"drugbank-id\": \"DB00490\", \"name\": \"Buspirone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine.\", \"drugbank-id\": \"DB00497\", \"name\": \"Oxycodone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.\", \"drugbank-id\": \"DB00502\", \"name\": \"Haloperidol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.\", \"drugbank-id\": \"DB00564\", \"name\": \"Carbamazepine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.\", \"drugbank-id\": \"DB00611\", \"name\": \"Butorphanol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00623\", \"name\": \"Fluphenazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine.\", \"drugbank-id\": \"DB00628\", \"name\": \"Clorazepate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pentazocine is combined with Dyclonine.\", \"drugbank-id\": \"DB00652\", \"name\": \"Pentazocine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Thioridazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00679\", \"name\": \"Thioridazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Midazolam is combined with Dyclonine.\", \"drugbank-id\": \"DB00683\", \"name\": \"Midazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Flurazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB00690\", \"name\": \"Flurazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Sufentanil is combined with Dyclonine.\", \"drugbank-id\": \"DB00708\", \"name\": \"Sufentanil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Risperidone is combined with Dyclonine.\", \"drugbank-id\": \"DB00734\", \"name\": \"Risperidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Isoflurane is combined with Dyclonine.\", \"drugbank-id\": \"DB00753\", \"name\": \"Isoflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Alfentanil is combined with Dyclonine.\", \"drugbank-id\": \"DB00802\", \"name\": \"Alfentanil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fentanyl is combined with Dyclonine.\", \"drugbank-id\": \"DB00813\", \"name\": \"Fentanyl\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Propofol is combined with Dyclonine.\", \"drugbank-id\": \"DB00818\", \"name\": \"Propofol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Diazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB00829\", \"name\": \"Diazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00831\", \"name\": \"Trifluoperazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Oxazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB00842\", \"name\": \"Oxazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dyclonine.\", \"drugbank-id\": \"DB00844\", \"name\": \"Nalbuphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Perphenazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00850\", \"name\": \"Perphenazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Levorphanol is combined with Dyclonine.\", \"drugbank-id\": \"DB00854\", \"name\": \"Levorphanol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Flupentixol is combined with Dyclonine.\", \"drugbank-id\": \"DB00875\", \"name\": \"Flupentixol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Triazolam is combined with Dyclonine.\", \"drugbank-id\": \"DB00897\", \"name\": \"Triazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Remifentanil is combined with Dyclonine.\", \"drugbank-id\": \"DB00899\", \"name\": \"Remifentanil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine.\", \"drugbank-id\": \"DB00924\", \"name\": \"Cyclobenzaprine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Zaleplon is combined with Dyclonine.\", \"drugbank-id\": \"DB00962\", \"name\": \"Zaleplon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Gabapentin is combined with Dyclonine.\", \"drugbank-id\": \"DB00996\", \"name\": \"Gabapentin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dyclonine.\", \"drugbank-id\": \"DB01075\", \"name\": \"Diphenhydramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dyclonine.\", \"drugbank-id\": \"DB01081\", \"name\": \"Diphenoxylate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pimozide is combined with Dyclonine.\", \"drugbank-id\": \"DB01100\", \"name\": \"Pimozide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Phenobarbital is combined with Dyclonine.\", \"drugbank-id\": \"DB01174\", \"name\": \"Phenobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Desflurane is combined with Dyclonine.\", \"drugbank-id\": \"DB01189\", \"name\": \"Desflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dyclonine.\", \"drugbank-id\": \"DB01192\", \"name\": \"Oxymorphone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Zopiclone is combined with Dyclonine.\", \"drugbank-id\": \"DB01198\", \"name\": \"Zopiclone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Estazolam is combined with Dyclonine.\", \"drugbank-id\": \"DB01215\", \"name\": \"Estazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ketamine is combined with Dyclonine.\", \"drugbank-id\": \"DB01221\", \"name\": \"Ketamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Quetiapine is combined with Dyclonine.\", \"drugbank-id\": \"DB01224\", \"name\": \"Quetiapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dyclonine.\", \"drugbank-id\": \"DB01236\", \"name\": \"Sevoflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dyclonine.\", \"drugbank-id\": \"DB01238\", \"name\": \"Aripiprazole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Paliperidone is combined with Dyclonine.\", \"drugbank-id\": \"DB01267\", \"name\": \"Paliperidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Amobarbital is combined with Dyclonine.\", \"drugbank-id\": \"DB01351\", \"name\": \"Amobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dyclonine.\", \"drugbank-id\": \"DB01440\", \"name\": \"Gamma Hydroxybutyric Acid\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dyclonine.\", \"drugbank-id\": \"DB01551\", \"name\": \"Dihydrocodeine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Bromazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB01558\", \"name\": \"Bromazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Quazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB01589\", \"name\": \"Quazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB01595\", \"name\": \"Nitrazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Thiothixene is combined with Dyclonine.\", \"drugbank-id\": \"DB01623\", \"name\": \"Thiothixene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dyclonine.\", \"drugbank-id\": \"DB01624\", \"name\": \"Zuclopenthixol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Asenapine is combined with Dyclonine.\", \"drugbank-id\": \"DB06216\", \"name\": \"Asenapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dyclonine.\", \"drugbank-id\": \"DB06690\", \"name\": \"Nitrous oxide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine.\", \"drugbank-id\": \"DB08815\", \"name\": \"Lurasidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Baclofen is combined with Dyclonine.\", \"drugbank-id\": \"DB00181\", \"name\": \"Baclofen\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Butalbital is combined with Dyclonine.\", \"drugbank-id\": \"DB00241\", \"name\": \"Butalbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Phenytoin is combined with Dyclonine.\", \"drugbank-id\": \"DB00252\", \"name\": \"Phenytoin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Topiramate is combined with Dyclonine.\", \"drugbank-id\": \"DB00273\", \"name\": \"Topiramate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clemastine is combined with Dyclonine.\", \"drugbank-id\": \"DB00283\", \"name\": \"Clemastine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dyclonine.\", \"drugbank-id\": \"DB00321\", \"name\": \"Amitriptyline\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tolcapone is combined with Dyclonine.\", \"drugbank-id\": \"DB00323\", \"name\": \"Tolcapone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Cetirizine is combined with Dyclonine.\", \"drugbank-id\": \"DB00341\", \"name\": \"Cetirizine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Protriptyline is combined with Dyclonine.\", \"drugbank-id\": \"DB00344\", \"name\": \"Protriptyline\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clobazam is combined with Dyclonine.\", \"drugbank-id\": \"DB00349\", \"name\": \"Clobazam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dyclonine.\", \"drugbank-id\": \"DB00356\", \"name\": \"Chlorzoxazone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dyclonine.\", \"drugbank-id\": \"DB00395\", \"name\": \"Carisoprodol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dyclonine.\", \"drugbank-id\": \"DB00405\", \"name\": \"Dexbrompheniramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Dyclonine.\", \"drugbank-id\": \"DB00423\", \"name\": \"Methocarbamol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Triprolidine is combined with Dyclonine.\", \"drugbank-id\": \"DB00427\", \"name\": \"Triprolidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dyclonine.\", \"drugbank-id\": \"DB00434\", \"name\": \"Cyproheptadine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Loratadine is combined with Dyclonine.\", \"drugbank-id\": \"DB00455\", \"name\": \"Loratadine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Imipramine is combined with Dyclonine.\", \"drugbank-id\": \"DB00458\", \"name\": \"Imipramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Entacapone is combined with Dyclonine.\", \"drugbank-id\": \"DB00494\", \"name\": \"Entacapone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Nortriptyline is combined with Dyclonine.\", \"drugbank-id\": \"DB00540\", \"name\": \"Nortriptyline\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Amoxapine is combined with Dyclonine.\", \"drugbank-id\": \"DB00543\", \"name\": \"Amoxapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Lamotrigine is combined with Dyclonine.\", \"drugbank-id\": \"DB00555\", \"name\": \"Lamotrigine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clonidine is combined with Dyclonine.\", \"drugbank-id\": \"DB00575\", \"name\": \"Clonidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dyclonine.\", \"drugbank-id\": \"DB00588\", \"name\": \"Fluticasone propionate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ethosuximide is combined with Dyclonine.\", \"drugbank-id\": \"DB00593\", \"name\": \"Ethosuximide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Efavirenz is combined with Dyclonine.\", \"drugbank-id\": \"DB00625\", \"name\": \"Efavirenz\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Metaxalone is combined with Dyclonine.\", \"drugbank-id\": \"DB00660\", \"name\": \"Metaxalone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tizanidine is combined with Dyclonine.\", \"drugbank-id\": \"DB00697\", \"name\": \"Tizanidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Trimipramine is combined with Dyclonine.\", \"drugbank-id\": \"DB00726\", \"name\": \"Trimipramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Meclizine is combined with Dyclonine.\", \"drugbank-id\": \"DB00737\", \"name\": \"Meclizine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Scopolamine is combined with Dyclonine.\", \"drugbank-id\": \"DB00747\", \"name\": \"Scopolamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dyclonine.\", \"drugbank-id\": \"DB00748\", \"name\": \"Carbinoxamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ethotoin is combined with Dyclonine.\", \"drugbank-id\": \"DB00754\", \"name\": \"Ethotoin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Olopatadine is combined with Dyclonine.\", \"drugbank-id\": \"DB00768\", \"name\": \"Olopatadine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clidinium is combined with Dyclonine.\", \"drugbank-id\": \"DB00771\", \"name\": \"Clidinium\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Primidone is combined with Dyclonine.\", \"drugbank-id\": \"DB00794\", \"name\": \"Primidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Brompheniramine is combined with Dyclonine.\", \"drugbank-id\": \"DB00835\", \"name\": \"Brompheniramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tiagabine is combined with Dyclonine.\", \"drugbank-id\": \"DB00906\", \"name\": \"Tiagabine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Zonisamide is combined with Dyclonine.\", \"drugbank-id\": \"DB00909\", \"name\": \"Zonisamide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Maprotiline is combined with Dyclonine.\", \"drugbank-id\": \"DB00934\", \"name\": \"Maprotiline\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Felbamate is combined with Dyclonine.\", \"drugbank-id\": \"DB00949\", \"name\": \"Felbamate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fexofenadine is combined with Dyclonine.\", \"drugbank-id\": \"DB00950\", \"name\": \"Fexofenadine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Desloratadine is combined with Dyclonine.\", \"drugbank-id\": \"DB00967\", \"name\": \"Desloratadine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ramelteon is combined with Dyclonine.\", \"drugbank-id\": \"DB00980\", \"name\": \"Ramelteon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dyclonine.\", \"drugbank-id\": \"DB00985\", \"name\": \"Dimenhydrinate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Guanfacine is combined with Dyclonine.\", \"drugbank-id\": \"DB01018\", \"name\": \"Guanfacine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clonazepam is combined with Dyclonine.\", \"drugbank-id\": \"DB01068\", \"name\": \"Clonazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Promethazine is combined with Dyclonine.\", \"drugbank-id\": \"DB01069\", \"name\": \"Promethazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Dyclonine.\", \"drugbank-id\": \"DB01080\", \"name\": \"Vigabatrin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dyclonine.\", \"drugbank-id\": \"DB01114\", \"name\": \"Chlorphenamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Doxepin is combined with Dyclonine.\", \"drugbank-id\": \"DB01142\", \"name\": \"Doxepin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Desipramine is combined with Dyclonine.\", \"drugbank-id\": \"DB01151\", \"name\": \"Desipramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Cyclizine is combined with Dyclonine.\", \"drugbank-id\": \"DB01176\", \"name\": \"Cyclizine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Levetiracetam is combined with Dyclonine.\", \"drugbank-id\": \"DB01202\", \"name\": \"Levetiracetam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dantrolene is combined with Dyclonine.\", \"drugbank-id\": \"DB01219\", \"name\": \"Dantrolene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Levodopa is combined with Dyclonine.\", \"drugbank-id\": \"DB01235\", \"name\": \"Levodopa\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Clomipramine is combined with Dyclonine.\", \"drugbank-id\": \"DB01242\", \"name\": \"Clomipramine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Dyclonine.\", \"drugbank-id\": \"DB01320\", \"name\": \"Fosphenytoin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Difenoxin is combined with Dyclonine.\", \"drugbank-id\": \"DB01501\", \"name\": \"Difenoxin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pipotiazine is combined with Dyclonine.\", \"drugbank-id\": \"DB01621\", \"name\": \"Pipotiazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Flunarizine is combined with Dyclonine.\", \"drugbank-id\": \"DB04841\", \"name\": \"Flunarizine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dyclonine.\", \"drugbank-id\": \"DB04844\", \"name\": \"Tetrabenazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Flibanserin is combined with Dyclonine.\", \"drugbank-id\": \"DB04908\", \"name\": \"Flibanserin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Iloperidone is combined with Dyclonine.\", \"drugbank-id\": \"DB04946\", \"name\": \"Iloperidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ezogabine is combined with Dyclonine.\", \"drugbank-id\": \"DB04953\", \"name\": \"Ezogabine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Methsuximide is combined with Dyclonine.\", \"drugbank-id\": \"DB05246\", \"name\": \"Methsuximide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pizotifen is combined with Dyclonine.\", \"drugbank-id\": \"DB06153\", \"name\": \"Pizotifen\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Levocetirizine is combined with Dyclonine.\", \"drugbank-id\": \"DB06282\", \"name\": \"Levocetirizine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ziconotide is combined with Dyclonine.\", \"drugbank-id\": \"DB06283\", \"name\": \"Ziconotide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Dyclonine.\", \"drugbank-id\": \"DB08872\", \"name\": \"Gabapentin Enacarbil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Pomalidomide is combined with Dyclonine.\", \"drugbank-id\": \"DB08910\", \"name\": \"Pomalidomide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Tasimelteon is combined with Dyclonine.\", \"drugbank-id\": \"DB09071\", \"name\": \"Tasimelteon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Stiripentol is combined with Dyclonine.\", \"drugbank-id\": \"DB09118\", \"name\": \"Stiripentol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Dyclonine.\", \"drugbank-id\": \"DB09128\", \"name\": \"Brexpiprazole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine.\", \"drugbank-id\": \"DB00176\", \"name\": \"Fluvoxamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine.\", \"drugbank-id\": \"DB00189\", \"name\": \"Ethchlorvynol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine.\", \"drugbank-id\": \"DB00228\", \"name\": \"Enflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine.\", \"drugbank-id\": \"DB00281\", \"name\": \"Lidocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.\", \"drugbank-id\": \"DB00292\", \"name\": \"Etomidate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine.\", \"drugbank-id\": \"DB00296\", \"name\": \"Ropivacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine.\", \"drugbank-id\": \"DB00297\", \"name\": \"Bupivacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine.\", \"drugbank-id\": \"DB00298\", \"name\": \"Dapiprazole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine.\", \"drugbank-id\": \"DB00313\", \"name\": \"Valproic Acid\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine.\", \"drugbank-id\": \"DB00391\", \"name\": \"Sulpiride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine.\", \"drugbank-id\": \"DB00409\", \"name\": \"Remoxipride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine.\", \"drugbank-id\": \"DB00508\", \"name\": \"Triflupromazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.\", \"drugbank-id\": \"DB00527\", \"name\": \"Cinchocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine.\", \"drugbank-id\": \"DB00599\", \"name\": \"Thiopental\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine.\", \"drugbank-id\": \"DB00633\", \"name\": \"Dexmedetomidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine.\", \"drugbank-id\": \"DB01106\", \"name\": \"Levocabastine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene.\", \"drugbank-id\": \"DB00647\", \"name\": \"Dextropropoxyphene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.\", \"drugbank-id\": \"DB00656\", \"name\": \"Trazodone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine.\", \"drugbank-id\": \"DB00721\", \"name\": \"Procaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine.\", \"drugbank-id\": \"DB00750\", \"name\": \"Prilocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.\", \"drugbank-id\": \"DB00752\", \"name\": \"Tranylcypromine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam.\", \"drugbank-id\": \"DB00801\", \"name\": \"Halazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine.\", \"drugbank-id\": \"DB00807\", \"name\": \"Proparacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital.\", \"drugbank-id\": \"DB00849\", \"name\": \"Methylphenobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine.\", \"drugbank-id\": \"DB00892\", \"name\": \"Oxybuprocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron.\", \"drugbank-id\": \"DB00904\", \"name\": \"Ondansetron\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.\", \"drugbank-id\": \"DB00907\", \"name\": \"Cocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine.\", \"drugbank-id\": \"DB00933\", \"name\": \"Mesoridazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.\", \"drugbank-id\": \"DB00961\", \"name\": \"Mepivacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine.\", \"drugbank-id\": \"DB01002\", \"name\": \"Levobupivacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane.\", \"drugbank-id\": \"DB01028\", \"name\": \"Methoxyflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin.\", \"drugbank-id\": \"DB01065\", \"name\": \"Melatonin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.\", \"drugbank-id\": \"DB01086\", \"name\": \"Benzocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.\", \"drugbank-id\": \"DB01154\", \"name\": \"Thiamylal\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.\", \"drugbank-id\": \"DB01159\", \"name\": \"Halothane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.\", \"drugbank-id\": \"DB01161\", \"name\": \"Chloroprocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone.\", \"drugbank-id\": \"DB01178\", \"name\": \"Chlormezanone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine.\", \"drugbank-id\": \"DB01209\", \"name\": \"Dezocine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.\", \"drugbank-id\": \"DB01227\", \"name\": \"Levomethadyl Acetate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.\", \"drugbank-id\": \"DB01239\", \"name\": \"Chlorprothixene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.\", \"drugbank-id\": \"DB01353\", \"name\": \"Butethal\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.\", \"drugbank-id\": \"DB01355\", \"name\": \"Hexobarbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium.\", \"drugbank-id\": \"DB01356\", \"name\": \"Lithium\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate.\", \"drugbank-id\": \"DB01433\", \"name\": \"Methadyl Acetate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide.\", \"drugbank-id\": \"DB01437\", \"name\": \"Glutethimide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine.\", \"drugbank-id\": \"DB01450\", \"name\": \"Dihydroetorphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin.\", \"drugbank-id\": \"DB01452\", \"name\": \"Heroin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine.\", \"drugbank-id\": \"DB01463\", \"name\": \"Fencamfamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine.\", \"drugbank-id\": \"DB01466\", \"name\": \"Ethylmorphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.\", \"drugbank-id\": \"DB01483\", \"name\": \"Barbital\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine.\", \"drugbank-id\": \"DB01497\", \"name\": \"Etorphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine.\", \"drugbank-id\": \"DB01525\", \"name\": \"Ecgonine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide.\", \"drugbank-id\": \"DB01529\", \"name\": \"Dextromoramide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil.\", \"drugbank-id\": \"DB01535\", \"name\": \"Carfentanil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam.\", \"drugbank-id\": \"DB01544\", \"name\": \"Flunitrazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.\", \"drugbank-id\": \"DB01545\", \"name\": \"Ethyl loflazepate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol.\", \"drugbank-id\": \"DB01547\", \"name\": \"Drotebanol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol.\", \"drugbank-id\": \"DB01555\", \"name\": \"Alphacetylmethadol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate.\", \"drugbank-id\": \"DB01563\", \"name\": \"Chloral hydrate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine.\", \"drugbank-id\": \"DB01565\", \"name\": \"Dihydromorphine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam.\", \"drugbank-id\": \"DB01567\", \"name\": \"Fludiazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.\", \"drugbank-id\": \"DB01580\", \"name\": \"Oxprenolol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.\", \"drugbank-id\": \"DB01587\", \"name\": \"Ketazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam.\", \"drugbank-id\": \"DB01588\", \"name\": \"Prazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine.\", \"drugbank-id\": \"DB01614\", \"name\": \"Acepromazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine.\", \"drugbank-id\": \"DB01615\", \"name\": \"Aceprometazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone.\", \"drugbank-id\": \"DB01618\", \"name\": \"Molindone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole.\", \"drugbank-id\": \"DB02207\", \"name\": \"7-Nitroindazole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine.\", \"drugbank-id\": \"DB02665\", \"name\": \"(1R,2S)-2-Phenylcyclopropanaminium\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylecgonine.\", \"drugbank-id\": \"DB04688\", \"name\": \"Methylecgonine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.\", \"drugbank-id\": \"DB04819\", \"name\": \"Methapyrilene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate.\", \"drugbank-id\": \"DB04827\", \"name\": \"Ethyl carbamate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone.\", \"drugbank-id\": \"DB04833\", \"name\": \"Methaqualone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene.\", \"drugbank-id\": \"DB04842\", \"name\": \"Fluspirilene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant.\", \"drugbank-id\": \"DB04872\", \"name\": \"Osanetant\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin.\", \"drugbank-id\": \"DB05232\", \"name\": \"Tetrodotoxin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Canertinib.\", \"drugbank-id\": \"DB05424\", \"name\": \"Canertinib\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole.\", \"drugbank-id\": \"DB06144\", \"name\": \"Sertindole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride.\", \"drugbank-id\": \"DB06288\", \"name\": \"Amisulpride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole.\", \"drugbank-id\": \"DB06470\", \"name\": \"clomethiazole\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Deramciclane.\", \"drugbank-id\": \"DB06512\", \"name\": \"Deramciclane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Adipiplon.\", \"drugbank-id\": \"DB06579\", \"name\": \"Adipiplon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.\", \"drugbank-id\": \"DB06594\", \"name\": \"Agomelatine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502.\", \"drugbank-id\": \"DB06671\", \"name\": \"PSD502\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.\", \"drugbank-id\": \"DB06716\", \"name\": \"Fospropofol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone.\", \"drugbank-id\": \"DB06738\", \"name\": \"Ketobemidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol.\", \"drugbank-id\": \"DB06770\", \"name\": \"Benzyl alcohol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE.\", \"drugbank-id\": \"DB08861\", \"name\": \"DPDPE\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone.\", \"drugbank-id\": \"DB08922\", \"name\": \"Perospirone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.\", \"drugbank-id\": \"DB08927\", \"name\": \"Amperozide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine.\", \"drugbank-id\": \"DB08986\", \"name\": \"Etifoxine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine.\", \"drugbank-id\": \"DB08987\", \"name\": \"Etidocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine.\", \"drugbank-id\": \"DB09009\", \"name\": \"Articaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam.\", \"drugbank-id\": \"DB09017\", \"name\": \"Brotizolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.\", \"drugbank-id\": \"DB09068\", \"name\": \"Vortioxetine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.\", \"drugbank-id\": \"DB09085\", \"name\": \"Tetracaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam.\", \"drugbank-id\": \"DB09166\", \"name\": \"Etizolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil.\", \"drugbank-id\": \"DB09174\", \"name\": \"Lofentanil\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone.\", \"drugbank-id\": \"DB09224\", \"name\": \"Melperone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine.\", \"drugbank-id\": \"DB09225\", \"name\": \"Zotepine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.\", \"drugbank-id\": \"DB09286\", \"name\": \"Pipamperone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine.\", \"drugbank-id\": \"DB09342\", \"name\": \"Propoxycaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.\", \"drugbank-id\": \"DB09345\", \"name\": \"Pramocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Opium.\", \"drugbank-id\": \"DB11130\", \"name\": \"Opium\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben.\", \"drugbank-id\": \"DB11148\", \"name\": \"Butamben\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol.\", \"drugbank-id\": \"DB11304\", \"name\": \"Phenoxyethanol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.\", \"drugbank-id\": \"DB11371\", \"name\": \"Alfaxalone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone.\", \"drugbank-id\": \"DB11376\", \"name\": \"Azaperone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin.\", \"drugbank-id\": \"DB11400\", \"name\": \"Doramectin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine.\", \"drugbank-id\": \"DB11428\", \"name\": \"Medetomidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine.\", \"drugbank-id\": \"DB11477\", \"name\": \"Xylazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine.\", \"drugbank-id\": \"DB11502\", \"name\": \"Butacaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine.\", \"drugbank-id\": \"DB11543\", \"name\": \"Romifidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine.\", \"drugbank-id\": \"DB11549\", \"name\": \"Tiletamine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tricaine methanesulfonate.\", \"drugbank-id\": \"DB11552\", \"name\": \"Tricaine methanesulfonate\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam.\", \"drugbank-id\": \"DB11555\", \"name\": \"Zolazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine.\", \"drugbank-id\": \"DB11556\", \"name\": \"Detomidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone.\", \"drugbank-id\": \"DB11609\", \"name\": \"Normethadone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Allopregnanolone.\", \"drugbank-id\": \"DB11859\", \"name\": \"Allopregnanolone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrahydropalmatine.\", \"drugbank-id\": \"DB12093\", \"name\": \"Tetrahydropalmatine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone.\", \"drugbank-id\": \"DB12184\", \"name\": \"Gepirone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam.\", \"drugbank-id\": \"DB12273\", \"name\": \"Ecopipam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Eltanolone.\", \"drugbank-id\": \"DB12308\", \"name\": \"Eltanolone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromperidol.\", \"drugbank-id\": \"DB12401\", \"name\": \"Bromperidol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Piritramide.\", \"drugbank-id\": \"DB12492\", \"name\": \"Piritramide\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride.\", \"drugbank-id\": \"DB12518\", \"name\": \"Raclopride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxethazaine.\", \"drugbank-id\": \"DB12532\", \"name\": \"Oxethazaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Indiplon.\", \"drugbank-id\": \"DB12590\", \"name\": \"Indiplon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ritanserin.\", \"drugbank-id\": \"DB12693\", \"name\": \"Ritanserin\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine.\", \"drugbank-id\": \"DB12710\", \"name\": \"Perazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tandospirone.\", \"drugbank-id\": \"DB12833\", \"name\": \"Tandospirone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Benperidol.\", \"drugbank-id\": \"DB12867\", \"name\": \"Benperidol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Sepranolone.\", \"drugbank-id\": \"DB12972\", \"name\": \"Sepranolone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride.\", \"drugbank-id\": \"DB13025\", \"name\": \"Tiapride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Norflurane.\", \"drugbank-id\": \"DB13116\", \"name\": \"Norflurane\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphaprodine.\", \"drugbank-id\": \"DB13160\", \"name\": \"Alphaprodine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Propanidid.\", \"drugbank-id\": \"DB13234\", \"name\": \"Propanidid\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Proxibarbal.\", \"drugbank-id\": \"DB13253\", \"name\": \"Proxibarbal\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Clothiapine.\", \"drugbank-id\": \"DB13256\", \"name\": \"Clothiapine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl chloride.\", \"drugbank-id\": \"DB13259\", \"name\": \"Ethyl chloride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Sultopride.\", \"drugbank-id\": \"DB13273\", \"name\": \"Sultopride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Trichloroethylene.\", \"drugbank-id\": \"DB13323\", \"name\": \"Trichloroethylene\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromisoval.\", \"drugbank-id\": \"DB13370\", \"name\": \"Bromisoval\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Medazepam.\", \"drugbank-id\": \"DB13437\", \"name\": \"Medazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Xenon.\", \"drugbank-id\": \"DB13453\", \"name\": \"Xenon\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenibut.\", \"drugbank-id\": \"DB13455\", \"name\": \"Phenibut\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Meptazinol.\", \"drugbank-id\": \"DB13478\", \"name\": \"Meptazinol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Mebicar.\", \"drugbank-id\": \"DB13522\", \"name\": \"Mebicar\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Veralipride.\", \"drugbank-id\": \"DB13523\", \"name\": \"Veralipride\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluperidol.\", \"drugbank-id\": \"DB13552\", \"name\": \"Trifluperidol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Diethyl ether.\", \"drugbank-id\": \"DB13598\", \"name\": \"Diethyl ether\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoperidine.\", \"drugbank-id\": \"DB13605\", \"name\": \"Phenoperidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenazocine.\", \"drugbank-id\": \"DB13606\", \"name\": \"Phenazocine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Loprazolam.\", \"drugbank-id\": \"DB13643\", \"name\": \"Loprazolam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluanisone.\", \"drugbank-id\": \"DB13665\", \"name\": \"Fluanisone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Quinisocaine.\", \"drugbank-id\": \"DB13683\", \"name\": \"Quinisocaine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Vinyl ether.\", \"drugbank-id\": \"DB13690\", \"name\": \"Vinyl ether\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dixyrazine.\", \"drugbank-id\": \"DB13784\", \"name\": \"Dixyrazine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Tilidine.\", \"drugbank-id\": \"DB13787\", \"name\": \"Tilidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Penfluridol.\", \"drugbank-id\": \"DB13791\", \"name\": \"Penfluridol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Clopenthixol.\", \"drugbank-id\": \"DB13841\", \"name\": \"Clopenthixol\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Lormetazepam.\", \"drugbank-id\": \"DB13872\", \"name\": \"Lormetazepam\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclopropane.\", \"drugbank-id\": \"DB13984\", \"name\": \"Cyclopropane\"}, {\"description\": \"Dyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.\", \"drugbank-id\": \"DB09266\", \"name\": \"Technetium Tc-99m tilmanocept\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.\", \"drugbank-id\": \"DB00898\", \"name\": \"Ethanol\"}, {\"description\": \"Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00484\", \"name\": \"Brimonidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.\", \"drugbank-id\": \"DB00476\", \"name\": \"Duloxetine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone.\", \"drugbank-id\": \"DB01149\", \"name\": \"Nefazodone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine.\", \"drugbank-id\": \"DB06700\", \"name\": \"Desvenlafaxine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran.\", \"drugbank-id\": \"DB04896\", \"name\": \"Milnacipran\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine.\", \"drugbank-id\": \"DB00285\", \"name\": \"Venlafaxine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran.\", \"drugbank-id\": \"DB08918\", \"name\": \"Levomilnacipran\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine.\", \"drugbank-id\": \"DB04884\", \"name\": \"Dapoxetine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.\", \"drugbank-id\": \"DB08953\", \"name\": \"Indalpine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.\", \"drugbank-id\": \"DB00215\", \"name\": \"Citalopram\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.\", \"drugbank-id\": \"DB00472\", \"name\": \"Fluoxetine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.\", \"drugbank-id\": \"DB00715\", \"name\": \"Paroxetine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.\", \"drugbank-id\": \"DB01104\", \"name\": \"Sertraline\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.\", \"drugbank-id\": \"DB01175\", \"name\": \"Escitalopram\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine.\", \"drugbank-id\": \"DB04832\", \"name\": \"Zimelidine\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone.\", \"drugbank-id\": \"DB09194\", \"name\": \"Etoperidone\"}, {\"description\": \"The risk or severity of adverse effects can be increased when Dyclonine is combined with Alaproclate.\", \"drugbank-id\": \"DB13233\", \"name\": \"Alaproclate\"}, {\"description\": \"Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00366\", \"name\": \"Doxylamine\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.\", \"drugbank-id\": \"DB01041\", \"name\": \"Thalidomide\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.\", \"drugbank-id\": \"DB00972\", \"name\": \"Azelastine\"}, {\"description\": \"Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB00450\", \"name\": \"Droperidol\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.\", \"drugbank-id\": \"DB00956\", \"name\": \"Hydrocodone\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.\", \"drugbank-id\": \"DB01403\", \"name\": \"Methotrimeprazine\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.\", \"drugbank-id\": \"DB01173\", \"name\": \"Orphenadrine\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.\", \"drugbank-id\": \"DB09117\", \"name\": \"Paraldehyde\"}, {\"description\": \"Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB08883\", \"name\": \"Perampanel\"}, {\"description\": \"Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB09072\", \"name\": \"Sodium oxybate\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.\", \"drugbank-id\": \"DB09034\", \"name\": \"Suvorexant\"}, {\"description\": \"Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.\", \"drugbank-id\": \"DB06204\", \"name\": \"Tapentadol\"}, {\"description\": \"Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.\", \"drugbank-id\": \"DB00425\", \"name\": \"Zolpidem\"}], \"drugbank_id\": \"DB00645\", \"experimental_properties\": {\"logp\": 3.7, \"melting_point\": \"174-175\", \"water_solubility\": \"Soluble (HCl salt)\"}, \"formula\": \"C18H27NO2\", \"groups\": \"approved\", \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchi_key\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"international_brands\": [{\"company\": \"AstraZeneca\", \"name\": \"Dyclone\"}, {\"company\": \"Insight Pharmaceuticals\", \"name\": \"Sucrets\"}], \"iupac\": \"1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one\", \"kegg_compound\": \"C07881\", \"manufacturers\": \"Astrazeneca lp\", \"mixtures\": [{\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Black Cherry\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Skin Shield\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Wild Cherry\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Childrens Cherry\"}, {\"ingredients\": \"Dyclonine + Menthol\", \"name\": \"Sucrets Complete Cool Citrus\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets MS Wintergreen\"}, {\"ingredients\": \"Dyclonine + Menthol\", \"name\": \"Sucrets Complete Vapor Cherry\"}, {\"ingredients\": \"Dyclonine + Glycerin\", \"name\": \"Cepacol Sore Throat\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets for Kids\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Sore Throat\"}, {\"ingredients\": \"Dyclonine + Menthol\", \"name\": \"Sucrets Complete\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets for Kids\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Sore Throat Spray 0.1% Cherry\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Extra Strength Mint Flav.loz 3mg\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Regular Strength Lemon Flav.loz 2mg\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sucrets Regular Strength Lemon Flavoured Lozenges\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Cepacol Sore Throat Spray\"}, {\"ingredients\": \"Allantoin + Dyclonine\", \"name\": \"Tanac Medicated Gel\"}, {\"ingredients\": \"Benzethonium + Dyclonine + Ethanol\", \"name\": \"Skin Shield Liquid Bandage\"}, {\"ingredients\": \"Dyclonine + Menthol + Pectin\", \"name\": \"Sucrets Complete Sore Throat, Cough and Irritation\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"Sore Throat Relief\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Dyclonine\", \"name\": \"PerioRinse\"}, {\"ingredients\": \"Dyclonine + Phenol\", \"name\": \"Ambix First Aid\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride and Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Dyclonine + Menthol + Pectin\", \"name\": \"Sucrets\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}, {\"ingredients\": \"Benzethonium + Dyclonine\", \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\"}], \"name\": \"Dyclonine\", \"packagers\": [\"Gallipot\", \"Long Wing International Inc.\"], \"pharmacology\": {\"absorption\": \"Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.\", \"affected_organisms\": \"Humans and other mammals\", \"description\": \"Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.\", \"half_life\": \"Approximately 30 to 60 minutes.\", \"indication\": \"Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.\", \"mechanism_of_action\": \"Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.\", \"pharmacodynamics\": \"Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.\", \"toxicity\": \"Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.\"}, \"pharmgkb\": \"PA164748037\", \"predicted_properties\": {\"bioavailability\": true, \"ghose_filter\": true, \"h_bond_acceptor_count\": 3, \"h_bond_donor_count\": 0, \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"iupac_name\": \"1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one\", \"logp\": 3.68, \"logs\": -3.8, \"mddr_like_rule\": false, \"molecular_formula\": \"C18H27NO2\", \"molecular_weight\": 289.4125, \"monoisotopic_weight\": 289.204179113, \"number_of_rings\": 2, \"physiological_charge\": 1, \"pka_(strongest_acidic)\": 15.88, \"pka_(strongest_basic)\": 8.36, \"polar_surface_area_(psa)\": 29.54, \"polarizability\": 35.14, \"refractivity\": 87.07, \"rotatable_bond_count\": 8, \"rule_of_five\": true, \"smiles\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1\", \"traditional_iupac_name\": \"dyclonine\", \"water_solubility\": \"4.60e-02 g/l\"}, \"products\": [{\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Cream\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Ambix First Aid\", \"ndc_product_code\": \"10038-250\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2013-08-22\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride and Dyclonine hydrochloride\", \"ndc_product_code\": \"0363-0210\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2012-01-12\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"30142-150\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-06\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"56104-040\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2018-01-03\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"41250-132\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2012-01-05\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"36800-382\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2014-07-10\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"46122-525\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-21\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"11822-0128\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-22\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"63941-546\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-11\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"15127-093\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-26\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"37808-512\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-22\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"68016-615\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2005-12-07\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"69256-037\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2014-07-10\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"0113-0134\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-20\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"63940-012\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2012-02-14\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"63868-045\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-19\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"59779-385\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2014-07-10\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"41520-089\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-19\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"ndc_product_code\": \"11673-629\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2017-12-01\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Cepacol Sore Throat\", \"ndc_product_code\": \"63824-781\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2011-05-20\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Spray\", \"dpd\": \"02238651\", \"ended_marketing_on\": \"2012-03-23\", \"generic\": false, \"name\": \"Cepacol Sore Throat Spray\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1999-07-01\", \"strength\": \"0.1 %\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Rinse\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"PerioRinse\", \"ndc_product_code\": \"70372-726\", \"otc\": true, \"route\": \"Dental; Oral; Topical; Transmucosal\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2016-06-16\", \"strength\": \".1 g/100mL\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Liquid\", \"fda_application_number\": \"part333A\", \"generic\": false, \"name\": \"Skin Shield\", \"ndc_product_code\": \"63736-293\", \"otc\": true, \"route\": \"Topical\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2010-06-01\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Liquid\", \"dpd\": \"00561371\", \"ended_marketing_on\": \"1998-02-16\", \"generic\": false, \"name\": \"Skin Shield Liquid Bandage\", \"otc\": true, \"route\": \"Topical\", \"source\": \"DPD\", \"started_marketing_on\": \"1983-12-31\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02241325\", \"generic\": false, \"name\": \"Sore Throat Relief\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"strength\": \"3 mg\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets\", \"ndc_product_code\": \"63736-567\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2014-11-04\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"ended_marketing_on\": \"2017-12-22\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets Black Cherry\", \"ndc_product_code\": \"63736-196\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-06-18\", \"strength\": \"3 mg/1\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"ended_marketing_on\": \"2017-12-22\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets Childrens Cherry\", \"ndc_product_code\": \"63736-902\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-07-28\", \"strength\": \"1.2 mg/1\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02275481\", \"generic\": false, \"name\": \"Sucrets Complete\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"2007-05-31\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"ended_marketing_on\": \"2017-12-22\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets Complete Cool Citrus\", \"ndc_product_code\": \"63736-910\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-07-28\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02427915\", \"generic\": false, \"name\": \"Sucrets Complete Sore Throat, Cough and Irritation\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets Complete Vapor Cherry\", \"ndc_product_code\": \"63736-920\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-07-31\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02087529\", \"ended_marketing_on\": \"1998-08-25\", \"generic\": false, \"name\": \"Sucrets Extra Strength Mint Flav.loz 3mg\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1994-12-31\", \"strength\": \"3 mg\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"01908693\", \"ended_marketing_on\": \"1998-08-25\", \"generic\": false, \"name\": \"Sucrets for Kids\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1992-12-31\", \"strength\": \"1.2 mg\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02229682\", \"generic\": false, \"name\": \"Sucrets for Kids\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1997-08-15\", \"strength\": \"1.2 mg\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets MS Wintergreen\", \"ndc_product_code\": \"63736-915\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-07-28\", \"strength\": \"3 mg/1\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02088444\", \"ended_marketing_on\": \"1998-08-25\", \"generic\": false, \"name\": \"Sucrets Regular Strength Lemon Flav.loz 2mg\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1994-12-31\", \"strength\": \"2 mg\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02229657\", \"ended_marketing_on\": \"2009-06-19\", \"generic\": false, \"name\": \"Sucrets Regular Strength Lemon Flavoured Lozenges\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1997-08-15\", \"strength\": \"2 mg\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Lozenge\", \"dpd\": \"02268604\", \"generic\": false, \"name\": \"Sucrets Sore Throat\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"2007-05-31\", \"strength\": \"3 mg\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Aerosol\", \"dpd\": \"01908707\", \"ended_marketing_on\": \"1996-09-12\", \"generic\": false, \"name\": \"Sucrets Sore Throat Spray 0.1% Cherry\", \"otc\": true, \"route\": \"Oral\", \"source\": \"DPD\", \"started_marketing_on\": \"1993-12-31\", \"strength\": \".1 %\"}, {\"approved\": true, \"country\": \"US\", \"dosage_form\": \"Lozenge\", \"ended_marketing_on\": \"2017-12-22\", \"fda_application_number\": \"part356\", \"generic\": false, \"name\": \"Sucrets Wild Cherry\", \"ndc_product_code\": \"63736-850\", \"otc\": true, \"route\": \"Oral\", \"source\": \"FDA NDC\", \"started_marketing_on\": \"2009-07-28\", \"strength\": \"2 mg/1\"}, {\"approved\": true, \"country\": \"Canada\", \"dosage_form\": \"Gel\", \"dpd\": \"02034859\", \"ended_marketing_on\": \"2006-07-12\", \"generic\": false, \"name\": \"Tanac Medicated Gel\", \"otc\": true, \"route\": \"Topical\", \"source\": \"DPD\", \"started_marketing_on\": \"1994-12-31\"}], \"pubchem_compound\": \"3180\", \"pubchem_substance\": \"46506697\", \"salts\": \"Dyclonine hydrochloride\", \"smiles\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1\", \"synonyms\": [\"1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone\", \"2-(1-Piperidyl)ethyl P-butoxyphenyl ketone\", \"3-Piperidino-4'-butoxypropiophenone\", \"4-Butoxy-beta-piperidinopropiophenone\", \"4-N-Butoxy-beta-(1-piperidyl)propiophenone\", \"4'-Butoxy-3-piperidinopropiophenone\", \"Diclonina\", \"Dyclocaine\", \"Dyclonin\", \"Dyclonine\", \"Dycloninum\"], \"targets\": {\"actions\": \"inhibitor\", \"general_function\": \"Voltage-gated sodium channel activity\", \"id\": \"BE0000177\", \"known_action\": \"yes\", \"name\": \"Sodium channel protein type 10 subunit alpha\", \"organism\": \"Human\", \"source\": \"Swiss-Prot\", \"specific_function\": \"Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.\", \"uniprot\": \"Q9Y5Y9\"}, \"taxonomy\": {\"alternative-parent\": [\"Alkyl aryl ethers\", \"Aryl alkyl ketones\", \"Azacyclic compounds\", \"Benzoyl derivatives\", \"Beta-amino ketones\", \"Hydrocarbon derivatives\", \"Organic oxides\", \"Organopnictogen compounds\", \"Phenol ethers\", \"Phenoxy compounds\", \"Piperidines\", \"Trialkylamines\"], \"class\": \"Organooxygen compounds\", \"description\": \"This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.\", \"direct-parent\": \"Alkyl-phenylketones\", \"kingdom\": \"Organic compounds\", \"subclass\": \"Carbonyl compounds\", \"substituent\": [\"Alkyl aryl ether\", \"Alkyl-phenylketone\", \"Amine\", \"Aromatic heteromonocyclic compound\", \"Aryl alkyl ketone\", \"Azacycle\", \"Benzenoid\", \"Benzoyl\", \"Beta-aminoketone\", \"Ether\", \"Hydrocarbon derivative\", \"Monocyclic benzene moiety\", \"Organic nitrogen compound\", \"Organic oxide\", \"Organoheterocyclic compound\", \"Organonitrogen compound\", \"Organopnictogen compound\", \"Phenol ether\", \"Phenoxy compound\", \"Piperidine\", \"Tertiary aliphatic amine\", \"Tertiary amine\"], \"superclass\": \"Organic oxygen compounds\"}, \"therapeutic_targets_database\": \"DAP000509\", \"weight\": {\"average\": 289.4125, \"monoisotopic\": 289.204179113}, \"wikipedia\": \"Dyclonine\"}, \"drugcentral\": {\"_license\": \"https://goo.gl/QDNyNe\", \"approval\": {\"type\": \"FDA\"}, \"bioactivity\": {\"act_source\": \"DRUGBANK\", \"action_type\": \"BLOCKER\", \"gene_name\": \"SCN10A\", \"moa\": \"1\", \"moa_source\": \"CHEMBL\", \"swissprot\": \"SCNAA_HUMAN\", \"target\": \"Sodium channel protein type 10 subunit alpha\", \"target_class\": \"Ion channel\", \"uniprot_id\": \"Q9Y5Y9\"}, \"drug_use\": [{\"relation\": \"contraindication\", \"snomed_id\": \"51551000\", \"snomed_name\": \"Bleeding hemorrhoids\"}, {\"relation\": \"indication\"}, {\"relation\": \"indication\", \"snomed_id\": \"386761002\", \"snomed_name\": \"Local anesthesia\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"44808001\", \"snomed_name\": \"Conduction disorder of the heart\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"128613002\", \"snomed_name\": \"Seizure disorder\"}, {\"relation\": \"indication\"}, {\"relation\": \"indication\", \"snomed_id\": \"367466007\", \"snomed_name\": \"Skin irritation\"}, {\"relation\": \"indication\"}, {\"relation\": \"indication\", \"snomed_id\": \"418363000\", \"snomed_name\": \"Itching of skin\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"95351003\", \"snomed_name\": \"Disorder of mucous membrane\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"125643001\", \"snomed_name\": \"Open wound\"}, {\"relation\": \"indication\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"418242004\", \"snomed_name\": \"Denuded skin\"}, {\"relation\": \"contraindication\", \"snomed_id\": \"80954004\", \"snomed_name\": \"Decreased respiratory function\"}], \"pharmacology_action\": [{\"class_code\": \"D000777\", \"name\": \"Anesthetics\", \"source\": \"MeSH\", \"type\": \"PA\"}, {\"class_code\": \"D000779\", \"name\": \"Anesthetics, Local\", \"source\": \"MeSH\", \"type\": \"PA\"}, {\"class_code\": \"CHEBI:48425\", \"name\": \"topical anaesthetic\", \"source\": \"CHEBI\", \"type\": \"has role\"}, {\"class_code\": \"D002491\", \"name\": \"Central Nervous System Agents\", \"source\": \"MeSH\", \"type\": \"PA\"}, {\"class_code\": \"D002492\", \"name\": \"Central Nervous System Depressants\", \"source\": \"MeSH\", \"type\": \"PA\"}, {\"class_code\": \"D018689\", \"name\": \"Sensory System Agents\", \"source\": \"MeSH\", \"type\": \"PA\"}], \"struct_id\": 974, \"structures\": {\"cas_rn\": \"586-60-7\", \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"inn\": \"dyclonine\", \"smiles\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1\"}, \"synonyms\": [\"dyclonine\", \"dyclonine hydrochloride\", \"dyclocaine\", \"dyclonin\", \"dyclonine HCl\"], \"xref\": {\"chebi\": \"CHEBI:4724\", \"chembl_id\": [\"CHEMBL1200478\", \"CHEMBL1201217\"], \"drugbank_id\": \"DB00645\", \"inn_id\": \"640\", \"iuphar_ligand_id\": \"7173\", \"kegg_drug\": \"D00735\", \"mesh_supplemental_record_ui\": \"C100063\", \"nddf\": \"005055\", \"ndfrt\": [\"N0000147831\", \"N0000006380\"], \"nui\": \"N0000147831\", \"pubchem_cid\": \"3180\", \"rxnorm\": \"23744\", \"secondary_cas_rn\": \"536-43-6\", \"snomedct_us\": [\"23564005\", \"370307004\"], \"umlscui\": \"C0058831\", \"unii\": \"ZEC193879Q\", \"vandf\": \"4019739\", \"vuid\": \"4019739\"}}, \"ginas\": {\"_license\": \"?\", \"access\": [], \"approvalID\": \"078A24Q30O\", \"approved\": 1466087721342, \"approvedBy\": \"FDA_SRS\", \"cas_primary\": \"586-60-7\", \"codes\": [{\"access\": [], \"code\": \"N01BX02\", \"codeSystem\": \"WHO-ATC\", \"comments\": \"ATC|NERVOUS SYSTEM|ANESTHETICS|ANESTHETICS, LOCAL|Other local anesthetics|dyclonine\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.whocc.no/atc_ddd_index/?code=N01BX02&showdescription=yes\"}, {\"access\": [], \"code\": \"R02AD04\", \"codeSystem\": \"WHO-ATC\", \"comments\": \"ATC|RESPIRATORY SYSTEM|THROAT PREPARATIONS|THROAT PREPARATIONS|Anesthetics, local|dyclonine\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.whocc.no/atc_ddd_index/?code=R02AD04&showdescription=yes\"}, {\"access\": [], \"code\": \"QR02AD04\", \"codeSystem\": \"WHO-VATC\", \"comments\": \"VATC|THROAT PREPARATIONS|THROAT PREPARATIONS|Anesthetics, local|dyclonine\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.whocc.no/atcvet/atcvet_index/?code=QR02AD04&showdescription=yes\"}, {\"access\": [], \"code\": \"QN01BX02\", \"codeSystem\": \"WHO-VATC\", \"comments\": \"VATC|ANESTHETICS|ANESTHETICS, LOCAL|Other local anesthetics|dyclonine\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.whocc.no/atcvet/atcvet_index/?code=QN01BX02&showdescription=yes\"}, {\"access\": [], \"code\": \"586-60-7\", \"codeSystem\": \"CAS\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://chem.sis.nlm.nih.gov/chemidplus/direct.jsp?regno=586-60-7&result=advanced\"}, {\"access\": [], \"code\": \"C29015\", \"codeSystem\": \"NCI_THESAURUS\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&version=15.09d&ns=NCI_Thesaurus&code=C29015\"}, {\"access\": [], \"code\": \"C100063\", \"codeSystem\": \"MESH\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.ncbi.nlm.nih.gov/mesh/67100063\"}, {\"access\": [], \"code\": \"DYCLONINE\", \"codeSystem\": \"WIKIPEDIA\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://en.wikipedia.org/wiki/Dyclonine\"}, {\"access\": [], \"code\": \"SUB06432MIG\", \"codeSystem\": \"EVMPD\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\"}, {\"access\": [], \"code\": \"640\", \"codeSystem\": \"INN\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"https://mednet-communities.net/inn/db/ViewINN.aspx?i=640\"}, {\"access\": [], \"code\": \"7173\", \"codeSystem\": \"IUPHAR\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7173\"}, {\"access\": [], \"code\": \"23744\", \"codeSystem\": \"RXCUI\", \"comments\": \"RxNorm\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"https://rxnav.nlm.nih.gov/REST/rxcui/23744/allProperties.xml?prop=all\"}, {\"access\": [], \"code\": \"M4790\", \"codeSystem\": \"MERCK INDEX\", \"comments\": \"Merck Index\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"https://www.rsc.org/Merck-Index/monograph/M4790?q=authorize\"}, {\"access\": [], \"code\": \"DB00645\", \"codeSystem\": \"DRUG BANK\", \"references\": [\"a41979df-a043-4b2f-aff9-fad9015ed971\"], \"type\": \"PRIMARY\", \"url\": \"http://www.drugbank.ca/drugs/DB00645\"}], \"definitionLevel\": \"COMPLETE\", \"deprecated\": false, \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"lastEditedBy\": \"FDA_SRS\", \"moieties\": [{\"atropisomerism\": \"No\", \"charge\": 0, \"count\": 1, \"definedStereo\": 0, \"ezCenters\": 0, \"formula\": \"C18H27NO2\", \"hash\": \"9L9HZG54KTG1\", \"molfile\": \"078A24Q30O\\n  Marvin  06161610242D          \\n\\n 21 22  0  0  0  0            999 V2000\\n    7.8496   -1.2245    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.7023   -1.6499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    6.4189   -1.2245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.9908   -1.2322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    5.7023   -2.4774    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.1330   -1.6499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.9908   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.2767   -1.6499    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    3.5601   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    3.5601   -1.2400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    4.2870   -0.0077    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.8486   -0.0181    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.5534   -1.6421    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    7.8368   -0.4047    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    2.1422   -0.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    1.4256   -0.0258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.7141   -0.4253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    8.5534    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    9.2752   -1.2245    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    0.0000   -0.0335    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n    9.2675   -0.3970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\\n  2  3  1  0  0  0  0\\n  3  6  1  0  0  0  0\\n  4  2  1  0  0  0  0\\n  5  2  2  0  0  0  0\\n  6  1  1  0  0  0  0\\n  7  4  2  0  0  0  0\\n  8  4  1  0  0  0  0\\n  9 10  1  0  0  0  0\\n 10  8  2  0  0  0  0\\n 11  7  1  0  0  0  0\\n 12  9  1  0  0  0  0\\n 13  1  1  0  0  0  0\\n 14  1  1  0  0  0  0\\n 15 12  1  0  0  0  0\\n 16 15  1  0  0  0  0\\n 17 16  1  0  0  0  0\\n 18 14  1  0  0  0  0\\n 19 13  1  0  0  0  0\\n 20 17  1  0  0  0  0\\n 21 18  1  0  0  0  0\\n 21 19  1  0  0  0  0\\n 11  9  2  0  0  0  0\\nM  END\\n\", \"mwt\": \"289.4125\", \"opticalActivity\": \"UNSPECIFIED\", \"stereoCenters\": 0, \"stereoComments\": \"\", \"stereochemistry\": \"ACHIRAL\"}], \"names\": [{\"access\": [], \"displayName\": true, \"domains\": [\"drug\"], \"languages\": [\"en\"], \"name\": \"DYCLONINE\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": true, \"references\": [\"a4d9bfdf-c98e-4390-a387-65b8a3b8e218\", \"1c01e380-4b95-4521-aa8a-dfe2f000b09c\", \"a137194c-9a61-40a8-9f03-f7fd3ab215f5\", \"d3422909-f22b-4b26-9ce7-57e26ff100ea\", \"56d9e1b4-4143-44c9-918b-a57705d54ebe\", \"37070530-a0e4-4c80-834e-f1231e69bfe1\", \"21ab7abe-a502-457e-86a3-4c90abb90585\", \"1972ce41-a70f-4449-bfe6-1645982c610a\", \"95746a98-ce8b-4962-ae91-fc6711db9ee2\"], \"stdName\": \"DYCLONINE\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [], \"languages\": [\"en\"], \"name\": \"1-PROPANONE, 1-(4-BUTOXYPHENYL)-3-(1-PIPERIDINYL)\", \"preferred\": false, \"references\": [\"95746a98-ce8b-4962-ae91-fc6711db9ee2\"], \"stdName\": \"1-PROPANONE, 1-(4-BUTOXYPHENYL)-3-(1-PIPERIDINYL)\", \"type\": \"cn\"}, {\"access\": [], \"displayName\": false, \"domains\": [], \"languages\": [\"en\"], \"name\": \"4'-BUTOXY-3-PIPERIDINOPROPIOPHENONE\", \"preferred\": false, \"references\": [\"95746a98-ce8b-4962-ae91-fc6711db9ee2\"], \"stdName\": \"4'-BUTOXY-3-PIPERIDINOPROPIOPHENONE\", \"type\": \"sys\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"ar\"], \"name\": \"\\u062f\\u064a\\u0643\\u0644\\u0648\\u0646\\u064a\\u0646\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"\\u062f\\u064a\\u0643\\u0644\\u0648\\u0646\\u064a\\u0646\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"fr\"], \"name\": \"dyclonine\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"dyclonine\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"la\"], \"name\": \"dycloninum\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"dycloninum\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"zh\"], \"name\": \"\\u8fbe\\u514b\\u7f57\\u5b81\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"\\u8fbe\\u514b\\u7f57\\u5b81\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"es\"], \"name\": \"diclonina\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"diclonina\", \"type\": \"of\"}, {\"access\": [], \"displayName\": false, \"domains\": [\"drug\"], \"languages\": [\"ru\"], \"name\": \"\\u0434\\u0438\\u043a\\u043b\\u043e\\u043d\\u0438\\u043d\", \"nameOrgs\": [{\"deprecated\": false, \"nameOrg\": \"INN\"}], \"preferred\": false, \"references\": [\"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"], \"stdName\": \"\\u0434\\u0438\\u043a\\u043b\\u043e\\u043d\\u0438\\u043d\", \"type\": \"of\"}], \"names_list\": [\"DYCLONINE\", \"1-PROPANONE, 1-(4-BUTOXYPHENYL)-3-(1-PIPERIDINYL)\", \"4'-BUTOXY-3-PIPERIDINOPROPIOPHENONE\", \"\\u062f\\u064a\\u0643\\u0644\\u0648\\u0646\\u064a\\u0646\", \"dyclonine\", \"dycloninum\", \"\\u8fbe\\u514b\\u7f57\\u5b81\", \"diclonina\", \"\\u0434\\u0438\\u043a\\u043b\\u043e\\u043d\\u0438\\u043d\"], \"notes\": [], \"preferred_name\": \"DYCLONINE\", \"properties\": [], \"references\": [{\"access\": [], \"citation\": \"USP Dictionary 2010:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"95746a98-ce8b-4962-ae91-fc6711db9ee2\"}, {\"access\": [], \"citation\": \"INN 2010:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"21ab7abe-a502-457e-86a3-4c90abb90585\"}, {\"access\": [], \"citation\": \"MERCK INDEX:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"56d9e1b4-4143-44c9-918b-a57705d54ebe\"}, {\"access\": [], \"citation\": \"WHO-DD:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"1c01e380-4b95-4521-aa8a-dfe2f000b09c\"}, {\"access\": [], \"citation\": \"NDF-RT:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"d3422909-f22b-4b26-9ce7-57e26ff100ea\"}, {\"access\": [], \"citation\": \"SRS CODE IMPORT:<SRS_LEGACY_DATA></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"documentDate\": \"2016-06-16T10:35:21.000-0400\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"a41979df-a043-4b2f-aff9-fad9015ed971\"}, {\"access\": [], \"citation\": \"SRS import [078A24Q30O]:<SRS_LEGACY_DATA><CREATED_BY></CREATED_BY><CREATED_DATE>null</CREATED_DATE></SRS_LEGACY_DATA>\", \"docType\": \"SRS\", \"documentDate\": \"2016-06-16T10:35:21.000-0400\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"url\": \"http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=078A24Q30O\", \"uuid\": \"8ee17e9e-01e6-4c31-b004-bca59c27e736\"}, {\"access\": [], \"citation\": \"USP Dictionary 2010\", \"docType\": \"SRS\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"uuid\": \"ecf6fc00-b597-42e5-b594-e834c44e5112\"}, {\"access\": [], \"citation\": \"INN proposed list:6\", \"docType\": \"INN\", \"publicDomain\": true, \"tags\": [\"NOMEN\"], \"url\": \"http://www.who.int/entity/medicines/publications/druginformation/innlists/PL6.pdf\", \"uuid\": \"fc2d70c9-d7cb-4eef-a384-03d9aaa63aab\"}, {\"citation\": \"DYCLONINE [INN]\", \"docType\": \"SRS_LOCATOR\", \"publicDomain\": true, \"uuid\": \"37070530-a0e4-4c80-834e-f1231e69bfe1\"}, {\"citation\": \"DYCLONINE [MI]\", \"docType\": \"SRS_LOCATOR\", \"publicDomain\": true, \"uuid\": \"a4d9bfdf-c98e-4390-a387-65b8a3b8e218\"}, {\"citation\": \"DYCLONINE [WHO-DD]\", \"docType\": \"SRS_LOCATOR\", \"publicDomain\": true, \"uuid\": \"a137194c-9a61-40a8-9f03-f7fd3ab215f5\"}, {\"citation\": \"DYCLONINE [VANDF]\", \"docType\": \"SRS_LOCATOR\", \"publicDomain\": true, \"uuid\": \"1972ce41-a70f-4449-bfe6-1645982c610a\"}], \"relationships\": [{\"access\": [], \"comments\": \"\", \"references\": [], \"relatedSubstance\": {\"approvalID\": \"078A24Q30O\", \"refPname\": \"DYCLONINE\", \"refuuid\": \"aa8fedf9-3aef-47e9-8814-850a58de444b\", \"substanceClass\": \"reference\"}, \"type\": \"ACTIVE MOIETY\"}, {\"access\": [], \"comments\": \"\", \"references\": [], \"relatedSubstance\": {\"approvalID\": \"ZEC193879Q\", \"refPname\": \"DYCLONINE HYDROCHLORIDE\", \"refuuid\": \"45c5d248-575b-440e-8bda-0896dbb31039\", \"substanceClass\": \"reference\"}, \"type\": \"SALT/SOLVATE->PARENT\"}], \"status\": \"approved\", \"structure\": {\"atropisomerism\": \"No\", \"charge\": 0, \"definedStereo\": 0, \"ezCenters\": 0, \"formula\": \"C18H27NO2\", \"hash\": \"9L9HZG54KTG1\", \"molfile\": \"\\n  Symyx   06151614312D 1   1.00000     0.00000     0\\n\\n 21 22  0     0  0            999 V2000\\n   12.6875   -1.9792    0.0000 N   0  0  3  0  0  0           0  0  0\\n    9.2167   -2.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n   10.3750   -1.9792    0.0000 C   0  0  0  0  0  0           0  0  0\\n    8.0667   -1.9917    0.0000 C   0  0  0  0  0  0           0  0  0\\n    9.2167   -4.0042    0.0000 O   0  0  0  0  0  0           0  0  0\\n   11.5292   -2.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n    8.0667   -0.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n    6.9125   -2.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n    5.7542   -0.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n    5.7542   -2.0042    0.0000 C   0  0  0  0  0  0           0  0  0\\n    6.9292   -0.0125    0.0000 C   0  0  0  0  0  0           0  0  0\\n    4.6042   -0.0292    0.0000 O   0  0  0  0  0  0           0  0  0\\n   13.8250   -2.6542    0.0000 C   0  0  0  0  0  0           0  0  0\\n   12.6667   -0.6542    0.0000 C   0  0  0  0  0  0           0  0  0\\n    3.4625   -0.6667    0.0000 C   0  0  0  0  0  0           0  0  0\\n    2.3042   -0.0417    0.0000 C   0  0  0  0  0  0           0  0  0\\n    1.1542   -0.6875    0.0000 C   0  0  0  0  0  0           0  0  0\\n   13.8250    0.0000    0.0000 C   0  0  0  0  0  0           0  0  0\\n   14.9917   -1.9792    0.0000 C   0  0  0  0  0  0           0  0  0\\n    0.0000   -0.0542    0.0000 C   0  0  0  0  0  0           0  0  0\\n   14.9792   -0.6417    0.0000 C   0  0  0  0  0  0           0  0  0\\n  2  3  1  0     0  0\\n  3  6  1  0     0  0\\n  4  2  1  0     0  0\\n  5  2  2  0     0  0\\n  6  1  1  0     0  0\\n  7  4  2  0     0  0\\n  8  4  1  0     0  0\\n  9 10  1  0     0  0\\n 10  8  2  0     0  0\\n 11  7  1  0     0  0\\n 12  9  1  0     0  0\\n 13  1  1  0     0  0\\n 14  1  1  0     0  0\\n 15 12  1  0     0  0\\n 16 15  1  0     0  0\\n 17 16  1  0     0  0\\n 18 14  1  0     0  0\\n 19 13  1  0     0  0\\n 20 17  1  0     0  0\\n 21 18  1  0     0  0\\n 21 19  1  0     0  0\\n 11  9  2  0     0  0\\nM  END\\n\", \"mwt\": \"289.4125\", \"opticalActivity\": \"UNSPECIFIED\", \"references\": [\"ecf6fc00-b597-42e5-b594-e834c44e5112\", \"8ee17e9e-01e6-4c31-b004-bca59c27e736\"], \"stereoCenters\": 0, \"stereoComments\": \"\", \"stereochemistry\": \"ACHIRAL\"}, \"substanceClass\": \"chemical\", \"tags\": [\"INN\", \"MI\", \"WHO-DD\", \"VANDF\"], \"unii\": \"078A24Q30O\", \"uuid\": \"aa8fedf9-3aef-47e9-8814-850a58de444b\", \"xrefs\": {\"CAS\": \"586-60-7\", \"DRUG BANK\": \"DB00645\", \"EVMPD\": \"SUB06432MIG\", \"INN\": \"640\", \"IUPHAR\": \"7173\", \"MERCK INDEX\": \"M4790\", \"MESH\": \"C100063\", \"NCI_THESAURUS\": \"C29015\", \"RXCUI\": \"23744\", \"WHO-ATC\": [\"R02AD04\", \"N01BX02\"], \"WHO-VATC\": [\"QR02AD04\", \"QN01BX02\"], \"WIKIPEDIA\": \"DYCLONINE\"}}, \"ndc\": [{\"_license\": \"?\", \"active_ingred_unit\": \"mg/29.6mL; mg/29.6mL\", \"active_numerator_strength\": \".06; .23\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Walgreen Company\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Liquid Bandage\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"0363-0210-30\", \"packagedescription\": \"29.6 mL in 1 BOTTLE, WITH APPLICATOR (0363-0210-30) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20120112\"}, \"product_id\": \"0363-0210_5e9924be-4d68-324a-e053-2a91aa0a8ec1\", \"productndc\": \"0363-0210\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Benzethonium chloride and Dyclonine hydrochloride\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20120112\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"g/g; g/g\", \"active_numerator_strength\": \".005; .005\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"CREAM\", \"labelername\": \"Organics Corporation of America dba Ambix Laboratories\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"DYCLONINE HYDROCHLORIDE and Phenol\", \"package\": [{\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"10038-250-25\", \"packagedescription\": \"1 TUBE in 1 BOX (10038-250-25)  > 25 g in 1 TUBE\"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20130822\"}, {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"10038-250-42\", \"packagedescription\": \"1 TUBE in 1 BOX (10038-250-42)  > 42.5 g in 1 TUBE\"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20130822\"}], \"product_id\": \"10038-250_b009a672-63ac-45f5-93ea-1a251e03dcde\", \"productndc\": \"10038-250\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Ambix First Aid\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20130822\", \"substancename\": \"DYCLONINE HYDROCHLORIDE; PHENOL\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mg/10mL; mg/10mL\", \"active_numerator_strength\": \".2; .75\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Meijer Distribution Inc\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Liquid Bandage\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"41250-132-10\", \"packagedescription\": \"10 mL in 1 BOTTLE, WITH APPLICATOR (41250-132-10) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20120105\"}, \"product_id\": \"41250-132_8d9fa281-cd9c-482f-94b3-04aa5c7cb2b6\", \"productndc\": \"41250-132\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20120105\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mg/10mL; mg/10mL\", \"active_numerator_strength\": \".2; .75\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"CVS Pharmacy\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Liquid Bandage\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"59779-385-03\", \"packagedescription\": \"10 mL in 1 BOTTLE, WITH APPLICATOR (59779-385-03) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20140710\"}, \"product_id\": \"59779-385_d83cf249-f82a-440a-9e21-61672c6acc5b\", \"productndc\": \"59779-385\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20140710\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mL/27mL; mL/27mL\", \"active_numerator_strength\": \".0532; .0997\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Insight Pharmaceuticals\", \"listing_record_certified_through\": \"20171231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"E\", \"nonproprietaryname\": \"Benzethonium Chloride and Dyclonine Hydrochloride\", \"package\": [{\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63736-293-36\", \"packagedescription\": \"36 BOX in 1 CASE (63736-293-36)  > 1 BOTTLE in 1 BOX > 29.6 mL in 1 BOTTLE\"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20100601\"}, {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63736-293-24\", \"packagedescription\": \"24 BOX in 1 CASE (63736-293-24)  > 1 BOTTLE in 1 BOX > 26.9 mL in 1 BOTTLE\"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20100601\"}], \"product_id\": \"63736-293_6265bf84-0828-494b-b781-55351012e3e4\", \"productndc\": \"63736-293\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Skin Shield\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20100601\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mg/1; mg/1\", \"active_numerator_strength\": \"3; 6\", \"applicationnumber\": \"part356\", \"dosageformname\": \"LOZENGE\", \"labelername\": \"Insight Pharmaceuticals\", \"listing_record_certified_through\": \"20171231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"E\", \"nonproprietaryname\": \"Dyclonine Hydrochloride and Menthol\", \"package\": [{\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63736-920-18\", \"packagedescription\": \"18 LOZENGE in 1 CANISTER (63736-920-18) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20090731\"}, {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63736-920-24\", \"packagedescription\": \"24 LOZENGE in 1 CANISTER (63736-920-24) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20090731\"}], \"product_id\": \"63736-920_69e602c4-85c4-4b79-ba38-f16063084cc1\", \"productndc\": \"63736-920\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Sucrets Complete\", \"proprietarynamesuffix\": \"Vapor Cherry\", \"routename\": \"ORAL\", \"startmarketingdate\": \"20090731\", \"substancename\": \"DYCLONINE HYDROCHLORIDE; MENTHOL\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"g/100mL; g/100mL\", \"active_numerator_strength\": \".1; 33\", \"applicationnumber\": \"part356\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Reckitt Benckiser LLC\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Dyclonine Hydrochloride and Glycerin\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63824-781-74\", \"packagedescription\": \"118 mL in 1 BOTTLE (63824-781-74) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20110520\"}, \"product_id\": \"63824-781_1823aecf-9e1f-4029-bf89-2c454ee9a9b0\", \"productndc\": \"63824-781\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Cepacol\", \"proprietarynamesuffix\": \"Sore Throat\", \"routename\": \"ORAL\", \"startmarketingdate\": \"20110520\", \"substancename\": \"DYCLONINE HYDROCHLORIDE; GLYCERIN\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mg/10mL; mg/10mL\", \"active_numerator_strength\": \".2; .75\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Harmon Store Inc.\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Liquid Bandage\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"63940-012-03\", \"packagedescription\": \"10 mL in 1 BOTTLE, WITH APPLICATOR (63940-012-03) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20120214\"}, \"product_id\": \"63940-012_5f3ac734-952b-77b7-e053-2991aa0a6431\", \"productndc\": \"63940-012\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20120214\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"mg/9mL; mg/9mL\", \"active_numerator_strength\": \".2; .75\", \"applicationnumber\": \"part333A\", \"dosageformname\": \"LIQUID\", \"labelername\": \"Chain Drug Consortium, LLC\", \"listing_record_certified_through\": \"20181231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"N\", \"nonproprietaryname\": \"Liquid Bandage\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"68016-615-00\", \"packagedescription\": \"9 mL in 1 BOTTLE, WITH APPLICATOR (68016-615-00) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20051207\"}, \"product_id\": \"68016-615_5f9ceb56-fbf4-b4ad-e053-2991aa0abd1b\", \"productndc\": \"68016-615\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"Benzethonium chloride Plus Dyclonine hydrochloride\", \"routename\": \"TOPICAL\", \"startmarketingdate\": \"20051207\", \"substancename\": \"BENZETHONIUM CHLORIDE; DYCLONINE HYDROCHLORIDE\"}, {\"_license\": \"?\", \"active_ingred_unit\": \"g/100mL\", \"active_numerator_strength\": \".1\", \"applicationnumber\": \"part356\", \"dosageformname\": \"RINSE\", \"labelername\": \"CENTURA PHARMACEUTICALS INC\", \"listing_record_certified_through\": \"20171231\", \"marketingcategoryname\": \"OTC MONOGRAPH NOT FINAL\", \"ndc_exclude_flag\": \"E\", \"nonproprietaryname\": \"DYCLONINE\", \"package\": {\"ndc_exclude_flag\": \"N\", \"package\": {\"ndcpackagecode\": \"70372-726-01\", \"packagedescription\": \"480 mL in 1 BOTTLE (70372-726-01) \"}, \"sample_package\": \"N\", \"startmarketingdate\": \"20160616\"}, \"product_id\": \"70372-726_34385375-1c3e-5ecd-e054-00144ff8d46c\", \"productndc\": \"70372-726\", \"producttypename\": \"HUMAN OTC DRUG\", \"proprietaryname\": \"PerioRinse\", \"routename\": \"DENTAL; ORAL; TOPICAL; TRANSMUCOSAL\", \"startmarketingdate\": \"20160616\", \"substancename\": \"DYCLONINE HYDROCHLORIDE\"}], \"pharmgkb\": {\"_license\": \"https://goo.gl/6ZW4iX\", \"brand_mixtures\": [\"Skin Shield Liquid Bandage (Alcohol Anhydrous + Benzethonium Chloride + Dyclonine Hydrochloride)\", \"Tanac Medicated Gel (Allantoin + Dyclonine Hydrochloride)\"], \"cross_references\": {\"cheb\": \"chebi\", \"chemspide\": \"chemspider\", \"drugban\": \"drugbank\", \"drugs_product_database_(dpd\": \"drugs_product_database_(dpd)\", \"kegg_compoun\": \"kegg_compound\", \"pubchem_compoun\": \"pubchem_compound\", \"pubchem_substanc\": \"pubchem_substance\", \"therapeutic_targets_databas\": \"therapeutic_targets_database\", \"web_resourc\": \"web_resource\"}, \"dosing_guideline\": \"No\", \"external_vocabulary\": {\"atc\": \"R02AD04(dyclonine)\", \"mesh\": \"C100063(dyclonine)\", \"ndfrt\": \"N0000147831(DYCLONINE)\", \"rxnorm\": \"23744(dyclonine)\", \"umls\": \"C0058831(dyclonine)\"}, \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"name\": \"dyclonine\", \"pharmgkb_accession_id\": \"PA164748037\", \"smiles\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2\", \"trade_names\": [\"Diclonia\", \"Diclonina\", \"Diclonina [INN-Spanish]\", \"Dyclocaine\", \"Dyclocainum\", \"Dyclone\", \"Dyclonin\", \"Dyclonine HCL\", \"Dyclonine hydrochloride\", \"Dycloninum [INN-Latin]\", \"Dyclothane\", \"Tanaclone\"], \"type\": \"Drug\"}, \"pubchem\": {\"_license\": \"https://goo.gl/Ztr5rl\", \"chiral_atom_count\": 0, \"chiral_bond_count\": 0, \"cid\": \"CID3180\", \"complexity\": 292, \"covalently-bonded_unit_count\": 1, \"defined_atom_stereocenter_count\": 0, \"defined_bond_stereocenter_count\": 0, \"exact_mass\": 289.204, \"formal_charge\": 0, \"heavy_atom_count\": 21, \"hydrogen_bond_acceptor_count\": 3, \"hydrogen_bond_donor_count\": 0, \"inchi\": \"InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3\", \"inchi_key\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"isotope_atom_count\": 0, \"iupac\": {\"traditional\": \"1-(4-butoxyphenyl)-3-piperidino-propan-1-one\"}, \"molecular_formula\": \"C18H27NO2\", \"molecular_weight\": 289.419, \"monoisotopic_weight\": 289.204, \"rotatable_bond_count\": 8, \"smiles\": {\"isomeric\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2\"}, \"tautomers_count\": 2, \"topological_polar_surface_area\": 29.5, \"undefined_atom_stereocenter_count\": 0, \"undefined_bond_stereocenter_count\": 0, \"xlogp\": 3.6}, \"unii\": {\"_license\": \"?\", \"inchikey\": \"BZEWSEKUUPWQDQ-UHFFFAOYSA-N\", \"ingredient_type\": \"INGREDIENT SUBSTANCE\", \"inn_id\": \"640\", \"molecular_formula\": \"C18H27NO2\", \"ncit\": \"C29015\", \"preferred_term\": \"DYCLONINE\", \"pubchem\": \"3180\", \"registry_number\": \"586-60-7\", \"rxcui\": \"23744\", \"smiles\": \"CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2\", \"unii\": \"078A24Q30O\"}}", "UniProt:O60884": "{\"max_score\": 14.796165, \"took\": 3, \"total\": 1, \"hits\": [{\"HGNC\": \"14884\", \"MIM\": \"611322\", \"Vega\": \"OTTHUMG00000133104\", \"_id\": \"10294\", \"_score\": 14.796165, \"accession\": {\"genomic\": [\"AC018845.7\", \"CH471092.1\", \"KF511225.1\", \"NC_000016.10\"], \"protein\": [\"AAH13044.1\", \"AAH15809.1\", \"BAG35864.1\", \"CAA04669.1\", \"CAA73791.1\", \"EAW82693.1\", \"EAW82694.1\", \"NP_005871.1\", \"O60884.1\"], \"rna\": [\"AF088046.1\", \"AJ001309.1\", \"AK313031.1\", \"BC013044.2\", \"BC015809.2\", \"BU677823.1\", \"DB097731.1\", \"NM_005880.3\", \"Y13350.1\"], \"translation\": [{\"protein\": \"AAH13044.1\", \"rna\": \"BC013044.2\"}, {\"protein\": \"NP_005871.1\", \"rna\": \"NM_005880.3\"}, {\"protein\": \"CAA73791.1\", \"rna\": \"Y13350.1\"}, {\"protein\": \"BAG35864.1\", \"rna\": \"AK313031.1\"}, {\"protein\": \"CAA04669.1\", \"rna\": \"AJ001309.1\"}, {\"protein\": \"AAH15809.1\", \"rna\": \"BC015809.2\"}]}, \"alias\": [\"CPR3\", \"DJ3\", \"DJA2\", \"DNAJ\", \"DNJ3\", \"HIRIP4\", \"PRO3015\", \"RDJ2\"], \"ensembl\": {\"gene\": \"ENSG00000069345\", \"protein\": [\"ENSP00000314030\", \"ENSP00000460104\", \"ENSP00000477579\"], \"transcript\": [\"ENST00000317089\", \"ENST00000563158\", \"ENST00000569553\", \"ENST00000617000\"], \"translation\": [{\"protein\": \"ENSP00000314030\", \"rna\": \"ENST00000317089\"}, {\"protein\": \"ENSP00000460104\", \"rna\": \"ENST00000563158\"}, {\"protein\": \"ENSP00000477579\", \"rna\": \"ENST00000617000\"}], \"type_of_gene\": \"protein_coding\"}, \"entrezgene\": 10294, \"exac\": {\"all\": {\"exp_lof\": 16.9542504978, \"exp_mis\": 143.627955446, \"exp_syn\": 59.3341433404, \"lof_z\": 3.83819258298381, \"mis_z\": 2.6784656561571, \"mu_lof\": 1.18895584304e-06, \"mu_mis\": 1.25940449658e-05, \"mu_syn\": 5.02750568952e-06, \"n_lof\": 1.0, \"n_mis\": 78.0, \"n_syn\": 59.0, \"p_li\": 0.985455360988873, \"p_null\": 1.48315451346589e-06, \"p_rec\": 0.0145431558566137, \"syn_z\": 0.0268921532205812}, \"bp\": 1239, \"cds_end\": 47007483, \"cds_start\": 46990940, \"n_exons\": 9, \"nonpsych\": {\"exp_lof\": 15.162924589, \"exp_mis\": 129.81485506, \"exp_syn\": 53.5208152658, \"lof_z\": 3.57201559189748, \"mis_z\": 3.09063346007544, \"mu_lof\": 1.18895584304e-06, \"mu_mis\": 1.25940449658e-05, \"mu_syn\": 5.02750568952e-06, \"n_lof\": 1.0, \"n_mis\": 60.0, \"n_syn\": 52.0, \"p_li\": 0.97543234050995, \"p_null\": 6.57814454072261e-06, \"p_rec\": 0.0245610813455088, \"syn_z\": 0.130882008705208}, \"nontcga\": {\"exp_lof\": 15.5801407973, \"exp_mis\": 132.119958327, \"exp_syn\": 54.5696417429, \"lof_z\": 3.64382370415299, \"mis_z\": 2.82253762052664, \"mu_lof\": 1.18895584304e-06, \"mu_mis\": 1.25940449658e-05, \"mu_syn\": 5.02750568952e-06, \"n_lof\": 1.0, \"n_mis\": 67.0, \"n_syn\": 53.0, \"p_li\": 0.976856422595422, \"p_null\": 4.64567542143199e-06, \"p_rec\": 0.0231389317291569, \"syn_z\": 0.134538567487857}, \"transcript\": \"ENST00000317089.5\"}, \"exons\": [{\"cdsend\": 46973572, \"cdsstart\": 46957028, \"chr\": \"16\", \"position\": [[46955361, 46957220], [46959002, 46959130], [46959274, 46959419], [46964610, 46964807], [46967512, 46967646], [46968083, 46968164], [46971348, 46971572], [46971895, 46971955], [46973494, 46973714]], \"strand\": -1, \"transcript\": \"NM_005880\", \"txend\": 46973714, \"txstart\": 46955361}], \"exons_hg19\": [{\"cdsend\": 47007483, \"cdsstart\": 46990940, \"chr\": \"16\", \"position\": [[46989273, 46991132], [46992914, 46993042], [46993186, 46993331], [46998522, 46998719], [47001424, 47001558], [47001995, 47002076], [47005260, 47005484], [47005807, 47005867], [47007405, 47007625]], \"strand\": -1, \"transcript\": \"NM_005880\", \"txend\": 47007625, \"txstart\": 46989273}], \"generif\": [{\"pubmed\": 18595009, \"text\": \"Rdj2 modulates G protein signaling and further suggest that chaperoning G proteins is an emerging theme of the J protein network.\"}, {\"pubmed\": 18684711, \"text\": \"Bag1 NEF increased refolding by Hsc70 and DJA2, as did the newly characterized NEF Hsp110\"}, {\"pubmed\": 19940115, \"text\": \"Hsp40 type 1 chaperones DJA1 (DNAJA1/Hdj2) and DJA2 (DNAJA2) as key modulators of hERG degradation\"}, {\"pubmed\": 23091061, \"text\": \"The DNAJA2 substrate release mechanism is essential for chaperone-mediated folding.\"}, {\"pubmed\": 24318877, \"text\": \"we combined the Hsp70-NEF pairs with cochaperones of the J protein family (DnaJA1, DnaJA2, DnaJB1, and DnaJB4) to generate 16 permutations.\"}], \"genomic_pos\": {\"chr\": \"16\", \"end\": 46973788, \"ensemblgene\": \"ENSG00000069345\", \"start\": 46955362, \"strand\": -1}, \"genomic_pos_hg19\": {\"chr\": \"16\", \"end\": 47007699, \"start\": 46989299, \"strand\": -1}, \"go\": {\"BP\": [{\"evidence\": \"TAS\", \"id\": \"GO:0008284\", \"pubmed\": 9383053, \"term\": \"positive regulation of cell proliferation\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0009408\", \"term\": \"response to heat\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0032781\", \"term\": \"positive regulation of ATPase activity\"}, {\"evidence\": \"IDA\", \"id\": \"GO:0042026\", \"pubmed\": 21231916, \"term\": \"protein refolding\"}], \"CC\": [{\"evidence\": \"IBA\", \"id\": \"GO:0005829\", \"term\": \"cytosol\"}, {\"evidence\": \"IDA\", \"id\": \"GO:0005829\", \"pubmed\": 21231916, \"term\": \"cytosol\"}, {\"evidence\": \"TAS\", \"id\": \"GO:0005829\", \"term\": \"cytosol\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0016020\", \"term\": \"membrane\"}, {\"evidence\": \"HDA\", \"id\": \"GO:0070062\", \"pubmed\": 19056867, \"term\": \"extracellular exosome\"}], \"MF\": [{\"evidence\": \"IDA\", \"id\": \"GO:0001671\", \"pubmed\": 24318877, \"term\": \"ATPase activator activity\"}, {\"evidence\": \"IPI\", \"id\": \"GO:0005515\", \"pubmed\": [22085931, 25036637], \"term\": \"protein binding\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0005524\", \"term\": \"ATP binding\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0031072\", \"term\": \"heat shock protein binding\"}, {\"evidence\": \"IEA\", \"id\": \"GO:0046872\", \"term\": \"metal ion binding\"}, {\"evidence\": \"IDA\", \"id\": \"GO:0051082\", \"pubmed\": 21231916, \"term\": \"unfolded protein binding\"}, {\"evidence\": \"IPI\", \"id\": \"GO:0051087\", \"pubmed\": 21231916, \"term\": \"chaperone binding\"}]}, \"homologene\": {\"genes\": [[9606, 10294], [10090, 56445], [10116, 84026], [6239, 3565862], [7955, 406814], [3702, 823531], [3702, 832267], [8364, 448048], [4530, 4333580], [4530, 4334359], [4896, 2539671], [4932, 855661], [5141, 3874567], [9031, 415744], [9544, 695169], [9598, 473274], [9615, 478143], [9913, 360006], [28985, 2895719], [33169, 4619974], [318829, 2678160]], \"id\": 21193}, \"interpro\": [{\"desc\": \"Heat shock protein DnaJ, cysteine-rich domain\", \"id\": \"IPR001305\", \"short_desc\": \"HSP_DnaJ_Cys-rich_dom\"}, {\"desc\": \"DnaJ domain\", \"id\": \"IPR001623\", \"short_desc\": \"DnaJ_domain\"}, {\"desc\": \"Chaperone DnaJ, C-terminal\", \"id\": \"IPR002939\", \"short_desc\": \"DnaJ_C\"}, {\"desc\": \"HSP40/DnaJ peptide-binding\", \"id\": \"IPR008971\", \"short_desc\": \"HSP40/DnaJ_pept-bd\"}, {\"desc\": \"Chaperone DnaJ\", \"id\": \"IPR012724\", \"short_desc\": \"DnaJ\"}, {\"desc\": \"DnaJ domain, conserved site\", \"id\": \"IPR018253\", \"short_desc\": \"DnaJ_domain_CS\"}], \"ipi\": \"IPI00032406\", \"map_location\": \"16q11.2\", \"name\": \"DnaJ heat shock protein family (Hsp40) member A2\", \"other_names\": [\"DnaJ (Hsp40) homolog, subfamily A, member 2\", \"HIRA interacting protein 4\", \"cell cycle progression 3 protein\", \"cell cycle progression restoration gene 3 protein\", \"dnaJ homolog subfamily A member 2\", \"renal carcinoma antigen NY-REN-14\"], \"pathway\": {\"kegg\": {\"id\": \"hsa04141\", \"name\": \"Protein processing in endoplasmic reticulum - Homo sapiens (human)\"}}, \"pfam\": [\"PF00226\", \"PF00684\", \"PF01556\"], \"pharmgkb\": \"PA27409\", \"prosite\": [\"PS50076\", \"PS51188\"], \"reagent\": {\"GNF_Qia_hs-genome_v1_siRNA\": [{\"id\": \"GNF169458\", \"relationship\": \"is\"}, {\"id\": \"GNF180364\", \"relationship\": \"is\"}, {\"id\": \"GNF191270\", \"relationship\": \"is\"}, {\"id\": \"GNF202176\", \"relationship\": \"is\"}], \"GNF_hs-ORFeome1_1_reads\": {\"id\": \"GNF157599\", \"relationship\": \"similar to\"}, \"GNF_hs-Origene\": {\"id\": \"GNF031491\", \"relationship\": \"is\"}, \"GNF_mm+hs-MGC\": [{\"id\": \"GNF003716\", \"relationship\": \"is\"}, {\"id\": \"GNF003717\", \"relationship\": \"is\"}], \"GNF_mm+hs_RetroCDNA\": [{\"id\": \"GNF234573\", \"relationship\": \"is\"}, {\"id\": \"GNF284811\", \"relationship\": \"is\"}], \"NOVART_hs-genome_siRNA\": [{\"id\": \"GNF100103\", \"relationship\": \"is\"}, {\"id\": \"GNF139758\", \"relationship\": \"is\"}]}, \"refseq\": {\"genomic\": \"NC_000016.10\", \"protein\": \"NP_005871.1\", \"rna\": \"NM_005880.3\", \"translation\": {\"protein\": \"NP_005871.1\", \"rna\": \"NM_005880.3\"}}, \"reporter\": {\"HG-U133_Plus_2\": [\"209157_at\", \"226994_at\"], \"HG-U95Av2\": \"34201_at\", \"HG-U95B\": \"51644_at\", \"HTA-2_0\": \"TC16001087.hg.1\", \"HuEx-1_0\": \"3690084\", \"HuGene-1_1\": \"8001185\", \"HuGene-2_1\": \"16826218\"}, \"retired\": [9237, 55499, 124142], \"summary\": \"The protein encoded by this gene belongs to the evolutionarily conserved DNAJ/HSP40 family of proteins, which regulate molecular chaperone activity by stimulating ATPase activity. DNAJ proteins may have up to 3 distinct domains: a conserved 70-amino acid J domain, usually at the N terminus; a glycine/phenylalanine (G/F)-rich region; and a cysteine-rich domain containing 4 motifs resembling a zinc finger domain. The product of this gene works as a cochaperone of Hsp70s in protein folding and mitochondrial protein import in vitro. [provided by RefSeq, Jul 2008].\", \"symbol\": \"DNAJA2\", \"taxid\": 9606, \"type_of_gene\": \"protein-coding\", \"umls\": {\"cui\": \"C1423023\"}, \"unigene\": \"Hs.368078\", \"uniprot\": {\"Swiss-Prot\": \"O60884\", \"TrEMBL\": [\"A0A087WT48\", \"A0A024R6S1\", \"I3L320\"]}, \"wikipedia\": {\"url_stub\": \"DNAJA2\"}}]}", "NCBIGene: 100847086": "{\"max_score\": 1.55, \"took\": 9, \"total\": 1, \"hits\": [{\"HGNC\": \"43456\", \"_id\": \"100847086\", \"_score\": 1.55, \"accession\": {\"genomic\": [\"AL358216.33\", \"NC_000010.11\"], \"rna\": [\"LM611615.1\", \"NR_049884.1\"]}, \"alias\": \"mir-5699\", \"ensembl\": {\"gene\": \"ENSG00000263511\", \"transcript\": \"ENST00000578903\", \"translation\": [], \"type_of_gene\": \"miRNA\"}, \"entrezgene\": 100847086, \"exons\": [{\"cdsend\": 641778, \"cdsstart\": 641778, \"chr\": \"10\", \"position\": [[641688, 641778]], \"strand\": -1, \"transcript\": \"NR_049884\", \"txend\": 641778, \"txstart\": 641688}], \"exons_hg19\": [{\"cdsend\": 687718, \"cdsstart\": 687718, \"chr\": \"10\", \"position\": [[687628, 687718]], \"strand\": -1, \"transcript\": \"NR_049884\", \"txend\": 687718, \"txstart\": 687628}], \"genomic_pos\": {\"chr\": \"10\", \"end\": 641778, \"ensemblgene\": \"ENSG00000263511\", \"start\": 641689, \"strand\": -1}, \"genomic_pos_hg19\": {\"chr\": \"10\", \"end\": 687718, \"start\": 687629, \"strand\": -1}, \"map_location\": \"10p15.3\", \"miRBase\": \"MI0019306\", \"name\": \"microRNA 5699\", \"other_names\": \"hsa-mir-5699\", \"refseq\": {\"genomic\": \"NC_000010.11\", \"rna\": \"NR_049884.1\"}, \"summary\": \"microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop. [provided by RefSeq, Sep 2009].\", \"symbol\": \"MIR5699\", \"taxid\": 9606, \"type_of_gene\": \"ncRNA\", \"umls\": {\"cui\": \"C3471092\"}}]}", "R-HSA-5579024": "[{\"dbId\": 5603087, \"displayName\": \"Defective MAT1A does not transfer Ado from ATP to L-Met\", \"stId\": \"R-HSA-5603087\", \"isInDisease\": true, \"isInferred\": false, \"name\": [\"Defective MAT1A does not transfer Ado from ATP to L-Met\"], \"releaseDate\": \"2014-12-11\", \"speciesName\": \"Homo sapiens\", \"isChimeric\": false, \"systematicName\": \"MAT1A mutants do not transfer Ado from ATP to L-Met\", \"className\": \"Reaction\", \"schemaClass\": \"FailedReaction\"}]"}